浙江东方基因生物制品股份有限公司
Zhejiang Orient Gene Biotech Co., LTD

CE-DOC-OG073
Version 2.0

EC Declaration of Conformity

In accordance with Directive 98/79/EC

Legal Manufacturer: *Zhejiang Orient Gene Biotech Co., Ltd*

Legal Manufacturer Address: *3787#, East Yangguang Avenue, Dipu Street, Anji 313300, Huzhou, Zhejiang, China*

Declares, that the products
Product Name and Model(s)

Myoglobin/CK-MB/Troponin I Combo Rapid Test Cassette (Whole Blood/Serum/Plasma)	GDCAR-W435a

Classification: *Other*
Conformity assessment route: *Annex III (EC DECLARATION OF CONFORMITY)*

We, the Manufacturer, herewith declare with sole responsibility that our product/s mentioned above meet/s the provisions of the Directive 98/79/EC of the European Parliament and of the Council on In-Vitro Diagnostic Medical Devices.

We hereby explicitly appoint

EC Representative's Name: Shanghai International Holding Corp. GmbH (Europe)

EC Representative's Address: Eiffestrasse 80, 20537 Hamburg, Germany

to act as our European Authorized Representative as defined in the aforementioned Directive.

I, the undersigned, hereby declare that the medical devices specified above conform with the directive 98/79/EC on in vitro diagnostic medical devices and pertinent essential requirements

Date Signed: March 4, 2022

Digitally signed by Monastîrschii Viorica
Date: 2023.12.27 14:08:46 EET
Reason: MoldSign Signature
Location: Moldova

Name of authorized signatory: Joyce Pang
Position held in the company: Vice-President

浙江东方基因生物制品股份有限公司
Zhejiang Orient Gene Biotech Co., LTD

CE-DOC-OG259
Version 2.0

EC Declaration of Conformity

In accordance with Directive 98/79/EC

Legal Manufacturer: *Zhejiang Orient Gene Biotech Co., Ltd*

Legal Manufacturer Address: *3787#, East Yangguang Avenue, Dipu Street, Anji 313300, Huzhou, Zhejiang, China*

Declares, that the products
Product Name and Model(s)

Clostridium difficile Toxin A&B Rapid Test Cassette (Feces)	GCCD(Toxin A/B)-602a

Classification: *Other*
Conformity assessment route: *Annex III (EC DECLARATION OF CONFORMITY)*

We, the Manufacturer, herewith declare with sole responsibility that our product/s mentioned above meet/s the provisions of the Directive 98/79/EC of the European Parliament and of the Council on In-Vitro Diagnostic Medical Devices.

We hereby explicitly appoint

EC Representative's Name: CMC Medical Devices & Drugs S.L

EC Representative's Address: C/Horacio Lengo Nº 18, CP 29006, Málaga, Spain

to act as our European Authorized Representative as defined in the aforementioned Directive.

I, the undersigned, hereby declare that the medical devices specified above conform with the directive 98/79/EC on in vitro diagnostic medical devices and pertinent essential requirements

Date Signed: May 25, 2022

Name of authorized signatory: Joyce Pang
Position held in the company: Vice-President

浙江东方基因生物制品股份有限公司
Zhejiang Orient Gene Biotech Co., LTD

CE-DOC-OG060
Version 1.0

EC Declaration of Conformity

In accordance with Directive 98/79/EC

Legal Manufacturer: *Zhejiang Orient Gene Biotech Co., Ltd*

Legal Manufacturer Address: *3787#, East Yangguang Avenue, Dipu Street, Anji 313300, Huzhou, Zhejiang, China*

Declares, that the products
Product Name and Model(s)

Fecal Occult Blood Rapid Test Strip (Feces)	GEFOB-601b
Fecal Occult Blood Rapid Test Cassette (Feces)	GEFOB-602b

Classification: *Other*
Conformity assessment route: *Annex III (EC DECLARATION OF CONFORMITY)*

We, the Manufacturer, herewith declare with sole responsibility that our product/s mentioned above meet/s the provisions of the Directive 98/79/EC of the European Parliament and of the Council on In-Vitro Diagnostic Medical Devices.

We hereby explicitly appoint

EC Representative's Name: Shanghai International Holding Corp. GmbH (Europe)

EC Representative's Address: Eiffestrasse 80, 20537 Hamburg, Germany

to act as our European Authorized Representative as defined in the aforementioned Directive.

I, the undersigned, hereby declare that the medical devices specified above conform with the directive 98/79/EC on in vitro diagnostic medical devices and pertinent essential requirements

Date Signed: November 28, 2017

Name of authorized signatory: Joyce Pang
Position held in the company: Vice-President

STATEMENT

We, Zhejiang Orient Gene Biotech Co., Ltd , having a registered office at 3787#, East Yangguang Avenue, Dipu Street Anji 313300, Huzhou, Zhejiang, China assign SRL SANMEDICO having a registered office at A. Corobceanu street 7A, apt. 9, Chişinău MD-2012, Moldova, as non-exclusive authorized representative for Orient Gene Brand product in correspondence with the conditions of directive 98/79/EEC.

We declare that the company mentioned above is authorized to register, notify, renew or modify the registration of medical devices on the territory of the Republic of Moldova.

This Statement letter will be valid from Feb.21th,2023 to Feb.20th, 2024.

Zhejiang Orient Gene Biotech Co., Ltd

General Manager:

Date:2023/2/21

地址：浙江省湖州市安吉县递铺镇阳光大道东段 3787 号
Add: **3787#, East Yangguang Avenue, Dipu Street Anji 313300, Huzhou, Zhejiang, China**
电话 Tel:+86-572-5226111　　传真 Fax: +86-572-5226222　邮编 P.C.:313300

ZERTIFIKAT ◆ CERTIFICATE ◆ 認證證書 ◆ СЕРТИФИКАТ ◆ CERTIFICADO ◆ CERTIFICAT

DAkkS Deutsche Akkreditierungsstelle D-ZM-11321-01-00

Product Service

Certificate

No. Q5 092305 0001 Rev. 01

Holder of Certificate: **Zhejiang Orient Gene Biotech Co., Ltd.**
3787#, East Yangguang Avenue, Dipu Street Anji
313300 Huzhou, Zhejiang
PEOPLE'S REPUBLIC OF CHINA

Certification Mark:

Scope of Certificate: **Design and Development, Production and Distribution of In Vitro Diagnostic Reagent and Instrument for the Detection of Drugs of Abuse, Fertility, Infectious Diseases, Oncology, Biochemistry, Cardiac Diseases, Allergic Disease based on Rapid Test, PCR and Liquid Biochip Method.**

The Certification Body of TÜV SÜD Product Service GmbH certifies that the company mentioned above has established and is maintaining a quality management system, which meets the requirements of the listed standard(s). All applicable requirements of the testing and certification regulation of TÜV SÜD Group have to be complied with. For details and certificate validity see: www.tuvsud.com/ps-cert?q=cert:Q5 092305 0001 Rev. 01

Report No.: SH2198802

Valid from: 2022-04-11
Valid until: 2024-03-16

Date, 2022-04-11

Christoph Dicks
Head of Certification/Notified Body

TÜV SÜD Product Service GmbH • Certification Body • Ridlerstraße 65 • 80339 Munich • Germany

TÜV®

ZERTIFIKAT ◆ CERTIFICATE ◆ 認證證書 ◆ СЕРТИФИКАТ ◆ CERTIFICADO ◆ CERTIFICAT

DAkkS Deutsche Akkreditierungsstelle D-ZM-11321-01-00

TÜV SÜD Product Service

Certificate

No. Q5 092305 0001 Rev. 01

Applied Standard(s):

EN ISO 13485:2016
Medical devices - Quality management systems - Requirements for regulatory purposes
(ISO 13485:2016)
DIN EN ISO 13485:2016

Facility(ies):

Zhejiang Orient Gene Biotech Co., Ltd.
3787#, East Yangguang Avenue, Dipu Street Anji, 313300
Huzhou, Zhejiang, PEOPLE'S REPUBLIC OF CHINA

See Scope of Certificate

.

TÜV SÜD Product Service GmbH • Certification Body • Ridlerstraße 65 • 80339 Munich • Germany

TÜV®

Fecal Occult Blood Rapid Test Cassette (Feces) CE

INTENDED USE

Fecal Occult Blood Rapid Test Cassette (Feces) is a rapid chromatographic immunoassay for the qualitative detection of human occult blood in feces by professional laboratories or physician's offices. It is useful to detect bleeding caused by a number of gastrointestinal disorders, e.g., diverticulitis, colitis, polyps, and colorectal cancer.
Fecal Occult Blood Rapid Test Cassette (Feces) is recommended for use in1) routine physical examinations, 2) hospital monitoring for bleeding in patients, and 3) screening for colorectal cancer or gastrointestinal bleeding from any source.

INTRODUCTION

Most of diseases can cause hidden blood in the stool. In the early stages, gastrointestinal problems such as colon cancer, ulcers, polyps, colitis, diverticulitis, and fissures may not show any visible symptoms, only occult blood. Traditional guaiac-based method lacks sensitivity and specificity, and has diet-restriction prior to the testing.
Fecal Occult Blood Rapid Test Cassette (Feces) is a rapid test to qualitatively detect low levels of fecal occult blood in feces. The test uses double antibod- sandwich assay to selectively detect as low as 50 ng/mL of hemoglobin or 6 µg hemoglobin/g feces. In addition, unlike the guaiac assays, the accuracy of the test is not affected by the diet of the patients.

PRINCIPLE

Fecal Occult Blood Rapid Test Cassette (Feces) is a lateral flow chromatographic immunoassay based on the principle of the double antibody-sandwich technique. The membrane is pre-coated with anti-hemoglobin antibodies on the test line region of the device. During testing, the specimen reacts with the colloidal gold coated withl anti-hemoglobin antibodies. The mixture migrates upward on the membrane chromatographically by capillary action to react with anti-hemoglobin antibodies on the membrane and generate a colored line. The presence of this colored line in the test region indicates a positive result, while its absence indicates a negative result. To serve as a procedural control, a colored line will always appear in the control line region indicating that proper volume of specimen has been added and membrane wicking has occurred.

MATERIALS PROVIDED

20 Test cassettes
20 Specimen collection tubes with buffer
1 Package insert

MATERIALS REQUIRED BUT NOT PROVIDED

1. Specimen collection containers 2. Clock or timer

STORAGE AND STABILITY

All reagents are ready to use as supplied. Store unused test device unopened at 2°C-30°C. If stored at 2°C-8°C, ensure that the test device is brought to room temperature before opening. The test is not stable out of the expiration date printed on the sealed pouch. Do not freeze the kit or expose the kit over 30°C.

PRECAUTIONS

1. For professional *in vitro* diagnostic use only.
2. This package insert must be read completely before performing the test. Failure to follow the insert gives inaccurate test results.
3. Do not use it if the tube/pouch is damaged or broken.
4. Test is for single use only. Do not re-use under any circumstances.
5. Do not use specimen with visible blood for the testing.
6. Handel all specimens as if they contain infectious agents. Observe established standard procedure for proper disposal of specimens.
7. Specimen extraction buffer contains Sodium Azide (0.1%). Avoid contact with skin or eyes. Do not ingest.
8. Wear protective clothing such as laboratory coats, disposable gloves and eye protection when specimens are assay.
9. Humidity and temperature can adversely affect results.
10. Do not perform the test in a room with strong air flow, ie. electric fan or strong airconditioning.

PATIENT PREPARATION

1. A specimen should not be collected from a patient with following conditions that may interfere with the test results:

- Menstrual bleeding
- Bleeding hemorrhoids
- Constipating bleeding
- Urinary bleeding.

2. Dietary restrictions are not necessary.
3. Alcohol and certain medications such as aspirin, indomethacin, phenylbutazone, reserpine, cortocosteroids, and nonsteroidal anti-inflammatory drugs may cause gastrointestinal irritation and subsequent bleeding, thus gives positive reactions. On the advice of the physician, such substances should be discontinued at least 48 hours prior to testing.

SPECIMEN COLLECTION AND PREPARATION

Consider any materials of human origin as infectious and handle them using standard biosafety procedures.
1. Collect a random sample of feces in a clean, dry receptacle.
2. Unscrew the top of the collection tube and remove the applicator stick.
3. Randomly pierce the fecal specimen in at least five (5) different sites.
4. Remove excess sample off the shaft and outer grooves. Be sure sample remains on inside grooves.
5. Replace the stick in the tube and tighten securely.
6. Shake the specimen collection bottle so that there is proper homogenisation of feces in buffer solution.

Note: Specimens prepared in the specimen collection tube may be stored at room temperature (15-30°C) for 3 days maximum, at 2-8°C for 7 days maximum or at -20°C for 3 months maximum if not tested within 1 hour after preparation.

TEST PROCEDURE

Allow the test cassette, specimen, and/or controls to reach room temperature (15-30°C) prior to testing.
1. Remove the test cassette from the foil pouch and use it as soon as possible. Best results will be obtained if the assay is performed within one hour.
2. Place the test cassette on a clean, flat surface.
3. Shake the specimen collection tube several times.
4. Hold the specimen collection tube upright and then unscrew and open the upper cap.
5. Squeeze 3 drops (~90 µL) of the sample solution in the sample well of the cassette and start the timer.
6. Wait for the colored line(s) to appear. Read results in 5 minutes. Do not interpret the result after 5 minutes.



INTERPRETATION OF RESULTS

(Please refer to the illustration above)
Positive: Two lines appear. One colored line should be in the control line region (C) and another apparent colored line should be in the test line region (T).
Negative: One colored line appears in the control line region(C). No line appears in the test line region (T).
Invalid: Control line fails to appear. The test should be repeated using a new cassette. If the problem persists, discontinue using the test kit immediately and contact your local distributor.
NOTE:
1. The intensity of color in the test region (T) may vary depending on the concentration of analytes present in the specimen. Therefore, any shade of color in the test region should be considered positive. Note that this is a qualitative test only, and

Fecal Occult Blood Rapid Test Cassette (Feces)

cannot determine the concentration of analytes in the specimen.
2. Insufficient specimen volume, incorrect operating procedure or expired tests are the most likely reasons for control band failure.

QUALITY CONTROL

An internal procedural control is included in the test. A colored line appearing in the control line region (C) is an internal procedural control. It confirms sufficient specimen volume, adequate membrane wicking and correctl procedural technique. Control standards are not supplied with this kit; however it is recommended that positive and negative controls be tested as a good laboratory practice to confirm the test procedure and to verify proper test performance.

LIMITATIONS

1. This test kit is to be used for the qualitative detection of human hemoglobin in fecal samples. A positive result suggests the presence of human hemoglobin in fecal samples. In addition to intestinal bleeding the presence of blood in stools may have other causes such as hemorrhoids, blood in urine etc.
2. Not all colorectal bleedings are due to precancerous or cancerous polyps. The information obtained by this test should be used in conjunction with other clinical findings and testing methods, such as colonoscopy gathered by the physician.
3. Negative results do not exclude bleeding since some polyps and colorectal region cancers can bleed intermittently or not at all. Additionally, blood may not be uniformly distributed in fecal samples. Colorectal polyps at an early stage may not bleed.
4. Urine and excessive dilution of sample with water from toilet bowl may cause erroneous test results. The use of a receptacle is recommended.
5. Feces specimens should not collect during the menstrual period and not three day before or afterwards, at bleeding due to constipation, bleeding haemorrhoids,or at taking rectally administered medication. It could cause false positive results.
6. This test may be less sensitive for detecting upper g.i. Bleeding because blood degrades as it passes through the g.i. Track.
7. The Fecal Occult Blood Rapid Test Cassette (Feces) is to aid indiagnosis and is not intended to replace other diagnostic procedures such as G.I. fibroscope, endoscopy, colonoscopy, or X-ray analysis. Test results should not be deemed conclusive with respect to the presence or absence of gastrointestinal bleeding or pathology. A positive result should be followed up with additional diagnostic procedures to determine the exact cause and source for the occult blood in the feces.

PERFORMANCE CHARACTERISTICS

1. Sensitivity: 99.6%
Fecal Occult Blood Rapid Test Cassette (Feces) can detect the levels of human occult blood as low as 50 ng/mL hemoglobin or 6 µg hemoglobin/g feces.
2. Prozone Effect:
It is observed that this FOB test can detect 2 mg/mL hemoglobin.
3. Specificity: 99.9%
Fecal Occult Blood Rapid Test Cassette (Feces) is specific to human hemoglobin. Specimen containing the following substances at the standard concentration was tested on both positive and negative controls and showed no effects on test results at standards concentration.

Substances	Concentrations (Diluted with the extraction buffer)
Beef hemoglobin	2 mg/mL
Chicken hemoglobin	0.5 mg/mL
Pig hemoglobin	0.5 mg/mL
Goat hemoglobin	0.5 mg/mL
Horse hemoglobin	20 mg/mL
Rabbit hemoglobin	0.06 mg/mL

REFERENCES

1. Simon J.B. Occult Blood Screening for Colorectal Carcinoma: A Critical Review, Gastroenterology, Vol. 1985;88:820.
2. Blebea J. and Ncpherson RA. False-Positive Guaiac Testing With Iodine, Arch Pathol Lab Med, 1985;109:437-40.

INDEX OF SYMBOLS

	Consult instructions for use		Tests per kit	EC REP	Authorized Representative
IVD	For *in vitro* diagnostic use only		Use by		Do not reuse
2°C 30°C	Store between 2~30°C	LOT	Lot Number	REF	Catalog#

Zhejiang Orient Gene Biotech Co.,Ltd
Address: 3787#, East Yangguang Avenue, Dipu Street,
Anji 313300, Huzhou, Zhejiang, China
Tel: +86-572-5226111 Fax: +86-572-5226222
Website: www.orientgene.com

EC REP Shanghai International Holding Corp. GmbH (Europe)
Add: Eiffestrasse 80, 20537 Hamburg, Germany

REF GEFOB-602b

Revision Date: 2023-04-18
B21056-04

Clostridium difficile Toxin A&B Rapid Test Cassette (Feces)

CE

INTENDED USE

The Clostridium difficile Toxin A&B Rapid Test Cassette (Feces) a rapid visual immunoassay for the qualitative, presumptive detection of Clostridium difficile Toxin A&B in human fecal specimens, as a screening test and as an aid in the diagnosis of Clostridium difficile infection.

INTRODUCTION

Clostridium difficile (C. difficile), a Gram-positive spore bearing anaerobic bacterium is the major aetiological agent of diarrhoea and colitis associated with antibiotics. C. difficile is the most common cause of health care-associated diarrhoea in developed countries and is a major source of nosocomial morbidity and mortality worldwide.

Disease due to C. difficile develops when the organism is allowed to proliferate in the colon, most commonly after antibiotic use has eliminated competing flora. C. difficile can release two high-molecular-weight toxins, toxin A and toxin B, which are responsible for the clinical manifestations, which range from mild, self-limited watery diarrhoea to fulminant pseudomembranous colitis, toxic megacolon and death.

Clostridium difficile Glutamate Dehydrogenase (GDH) is an enzyme produced in large quantities by all toxigenic and non-toxigenic strains, making it an excellent marker for the organism.

The toxigenic culture (TC) is used as the gold standard technique to determine Clostridium difficile infection. This method consists in culture and isolation of C. difficile from feces, followed by toxin testing of the isolate, a labor-intensive assay to obtain a result.

The Clostridium difficile Toxin A&B Rapid Test Cassette (Feces) is a rapid test to qualitatively detect Clostridium difficile Toxin A&B in human feces in 10 minutes. The test can be performed by untrained or minimally skilled personnel, without cumbersome laboratory equipment.

PRINCIPLE

The Clostridium difficile Toxin A&B Rapid Test Cassette (Feces) is a qualitative lateral flow immunoassay for the detection of Clostridium difficile Toxin A&B in human feces samples. The membrane is pre-coated with monoclonal antibodies against Toxin A on the A test line region and monoclonal antibodies against Toxin B on the B test line region. During testing, the sample reacts with the particle coated with anti-Toxin A and anti-Toxin B antibodies, which were pre-dried on the test strip. The mixture moves upward on the membrane by capillary action. If there is sufficient Clostridium difficile Toxin or Toxin B in the specimen, a colored band will form at the test region of the membrane. The presence of this colored band indicates a positive result, while its absence indicates a negative result. The appearance of a colored band at the control region serves as a procedural control, indicating that the proper volume of specimen has been added and membrane wicking has occurred. If the control line does not appear, the test result is not valid.

PRODUCT CONTENTS

The Clostridium difficile Toxin A&B Rapid Test Cassette (Feces) containing Clostridium difficile Toxin A and Toxin B antibodies coated particles and Toxin A-specific antibodies and Toxin B-specific antibodies coated on the membrane.

MATERIALS SUPPLIED

20 Test cassettes
20 Extraction tubes with buffer
1 Package insert

MATERIAL REQUIRED BUT NOT PROVIDED

Timer

STORAGE AND STABILITY

The kit can be stored at room temperature or refrigerated (2-30℃). The test cassette is stable through the expiration date printed on the sealed pouch. The test cassette must remain in the sealed pouch until use. DO NOT FREEZE. Do not use beyond the expiration date.

WARNINGS AND PRECAUTIONS

1. For professional *in vitro* diagnostic use only.
2. Do not use after the expiration date indicated on the package. Do not use the test if the foil pouch is damaged.
3. Test is for single use only. Do not re-use under any circumstances.
4. Avoid cross-contamination of specimens by using a new extraction tube for each specimen obtained.
5. Read the entire procedure carefully prior to testing.
6. Do not eat, drink or smoke in any area where specimens and kits are handled.
7. Handle all specimens as if they contain infectious agents. Observe established precautions against microbiological hazards throughout the procedure and follow standard procedures for the proper disposal of specimens. Wear protective clothing such as laboratory coats, disposable gloves and eye protection when specimens are assayed.
8. Do not interchange or mix reagents from different lots. Do not mix solution bottle caps.
9. Humidity and temperature can adversely affect results.
10. Do not perform the test in a room with strong air flow, ie. electric fan or strong airconditioning.

SPECIMEN COLLECTION AND PREPARATION

- The Clostridium difficile Toxin A&B Rapid Test Cassette (Feces) is intended for use with human fecal specimens only.
- Stool samples should be collected in clean containers. The samples can be stored in the refrigerator (2-8℃) for 7 days prior to testing. For longer storage, maximum 1 year, the specimen must be kept frozen a-20℃. In this case, the sample will be totally thawed and brought to room temperature before testing. Ensure only the amount needed is thawed because of freezing and defrosting cycles are not recommended. Homogenise stool samples as thoroughly as possible prior to preparation.

SPECIMEN PREPARATION

Consider any materials of human origin as infectious and handle them using standard biosafety procedures.

1. Collect a random sample of feces in a clean, dry receptacle. Best results will be obtained if the assay is performed within 6 hours after collection.
2. Unscrew and remove the dilution tube applicator. Be careful not to spill or spatter solution from the tube. Collect specimens by inserting the applicator stick into at least 5 different sites of the feces to collect approximately 50 mg of feces (equivalent to 1/4 of a pea).
3. **For liquid specimens:** Hold the pipette vertically, aspirate fecal specimens, and then transfer 3 drops (approximately 80 µL) into the specimen collection tube containing the extraction buffer.
4. Replace the stick in the tube and tighten securely.
5. Shake the specimen collection tube vigorously to mix the specimen and the extraction buffer. Specimens prepared in the specimen collection tube may be stored for 6 months at -20℃ if not tested within 1 hour after preparation.

TEST PROCEDURE

Bring tests, specimens, reagents and/or controls to room temperature (15-30℃) prior to testing.

1. Remove the test from the sealed pouch and place it on a clean, level surface. Label the device with patient or control identification. For best results, the assay should be performed immediately after opening the foil pouch.
2. Holding the sample collection device upright, carefully break off the tip of collection device.
3. Squeeze 3 drops (~90 µL) of the sample solution in the sample well of the device and start the timer.
4. Wait for the colored line(s) to appear. Read results in 10 minutes. Do not interpret the result after 10 minutes.



INTERPRETATION OF RESULTS

(Please refer to the illustration above)

1. Positive:

1.1 Toxin A Positive:

The presence of two lines as control line (C) and A test line within the result window indicates a positive result for Toxin A.

1.2 Toxin B Positive:
The presence of two lines as control line (C) and B test line within the result window indicates a positive result for Toxin B.
1.3 Toxin A& B Positive:
The presence of three lines as control line (C), A test line and B test line within the result window indicates a positive result for both Toxin A and Toxin B.
2. Negative:
One colored line appears in the control line region (C). No line appears in the test line region (T).
3. Invalid:
If the control band (C) is not visible within the result window after performing the test, the result is considered invalid. Some causes of invalid results are because of not following the directions correctly or the test may have deteriorated beyond the expiration date. It is recommended that the specimen be re-tested using a new test. If the problem persists, discontinue using the test kit immediately and contact your local distributor.

QUALITY CONTROL

A procedural control is included in the test. A red line appearing in the control region (C) is the internal procedural control. It confirms sufficient specimen volume and correct procedural technique. Control standards are not supplied with this test. However, it is recommended that positive and negative controls are sourced from a local competent authority and tested as a good laboratory practice, to confirm the test procedure and verify the test performance.

LIMITATIONS

1. The Clostridium difficile Toxin A&B Rapid Test Cassette (Feces) will only indicate the presence of parasites in the specimen (qualitative detection) and should be used for the detection of Clostridium difficile Toxin A&B in feces specimens only. Neither the quantitative value nor the rate of increase in antigen concentration can be determined by this test.
2. An excess of sample could cause wrong results (brown bands appear). Dilute the sample with the buffer and repeat the test.
3. The Clostridium difficile Toxin A&B Rapid Test Cassette (Feces) should be used only with samples from human feces. The use of other samples has not been established. The quality of the test depends on the quality of the sample; proper fecal specimens must be obtained.
4. A negative result is not meaningful because of it is possible the antigen concentration in the stool samples is lower than the detection limit value. If the symptoms or situation still persist, a Clostridium difficile determination should be carried out, on a sample from an enrichment culture.
5. As with all diagnostic tests, a definitive clinical diagnosis should not be based on the results of a single test, but should only be made by the physician after all clinical and laboratory findings have been evaluated.

PERFORMANCE CHARACTERISTICS

1. Clinical Sensitivity, Specificity and Accuracy

The Clostridium difficile Toxin A&B Rapid Test Cassette (Feces) has been evaluated with specimens obtained from patients. ELISA method was used as the reference method. The results show that the Clostridium difficile Toxin A&B Rapid Test Cassette (Feces) has a high overall relative accuracy.

Table 1: The Clostridium difficile Toxin A Rapid Test vs ELISA

Method		ELISA		Total Results
Clostridium difficile Toxin A&B Rapid Test Cassette	Results	Positive	Negative	
	Positive	43	1	44
	Negative	0	69	69
Total Results		43	70	113

Relative Sensitivity: 100%
Relative Specificity: 98.6%
Accuracy: 99.1%

Table 2: The Clostridium difficile Toxin B Rapid Test vs ELISA

Method		ELISA		Total Results
Clostridium difficile Toxin A&B Rapid Test Cassette	Results	Positive	Negative	
	Positive	36	1	37
	Negative	0	76	76
Total Results		36	77	113

Relative Sensitivity: 100%
Relative Specificity: 98.6%
Accuracy: 99.1%

2. Analytical Sensitivity

The Clostridium difficile Toxin A&B Rapid Test Cassette (Feces) was determined by testing serial dilutions of recombinant antigen. Detection limit values of Clostridium difficile Toxin A&B are 2 ng/mL for Toxin A and 1 ng/mL for Toxin B.

3. Cross-Reactivity

Cross-reactivity to samples positive for the following pathogens was tested and found to be negative:

Campylobacter coli	*Salmonella enteritidis*	*Shigella dysenteriae*
Campylobacter jejuni	*Salmonella paratyphi*	*Shigella flexneri*
E. Coli O157: H7	*Salmonella typhi*	*Shigella sonnei*
H. pylori	*Salmonella typhimurium*	*Staphliococcus aureus*
Listeria monocytogenes	*Shigella boydii*	*Yersinia enterocolitica*

REFERENCE

1. Knoop, F.C. et al.: Clostridium difficile: Clinical disease and diagnosis. Clin. Microbiol. Rev. (1993); 6: 251-265.
2. Kelly, C.P. et al.: Clostridium difficile Colitis. New Engl. J. Med. (1994); 330: 257-262.
3. Sullivan, N.M. et al.: Purification and characterization of toxins A and B of Clostridium difficile. Infect. Immun. (1982); 35: 1032-1040.
4. McDonald, L.C. et al.: An epidemic, toxin gene-variant strain of Clostridium difficile. N. Engl. J. Med. (2005); 353: 23.
5. Loo, V.G. et al.: A predominantly clonal multi-institutional outbreak of Clostridium difficile-associated diarrhea with high morbidity and mortality. N. Engl. J. Med. (2005); 353.23
6. Bartlett, J.G., Gerding, D.N.: Clinical recognition and diagnosis of Clostridium difficile infection. CID (2008); 46 (Suppl. 1): 12-18.

INDEX OF SYMBOLS

	Consult instructions for use	Σ	Tests per kit	EC REP	Authorized Representative
IVD	For *in vitro* diagnostic use only		Use by		Do not reuse
30°C 2°C	Store between 2~30°C	LOT	Lot Number	REF	Catalog#

Zhejiang Orient Gene Biotech Co.,Ltd
Address: 3787#, East Yangguang Avenue, Dipu Street,
Anji 313300, Huzhou, Zhejiang, China
Tel: +86-572-5226111 Fax: +86-572-5226222
Website: www.orientgene.com

EC REP CMC Medical Devices & Drugs S.L
C/Horacio Lengo Nº 18 CP 29006, Málaga-Spain
Tel: +34951214054 Fax: +34952330100
Email-info@cmcmedicaldevices.com

REF GCCD(Toxin A&B)-602a

Revision Date: 2022-02-21
B22718-01

Myoglobin/CK-MB/Troponin I Combo Test (Cassette)
(Whole Blood/Serum/Plasma)

A rapid test for the qualitative detection of Myoglobin, CK-MB, and Troponin I in whole blood, serum or plasma.
For professional in vitro diagnostic use only.

INTENDED USE

The Myoglobin/CK-MB/Troponin I Combo Test (Whole Blood/Serum/Plasma) is a rapid chromatographic immunoassay for the qualitative detection of human Myoglobin, CK-MB and cardiac Troponin I in whole blood , serum or plasma as an aid in the diagnosis of myocardial infarction (MI).

SUMMARY

Myoglobin (MYO), Creatine Kinase MB (CK-MB) and cardiac Troponin I (cTnI) are proteins released into the bloodstream after cardiac injury. Myoglobin is a heme-protein normally found in skeletal and cardiac muscle with a molecular weight of 17.8 kDa. It constitutes about 2 percent of total muscle protein and is responsible for transporting oxygen within muscle cells[1]. When muscle cells are damaged, Myoglobin is released into the blood rapidly due to its relatively small size. The level of Myoglobin increases measurably above baseline within 2-4 hours post-infarct, peaking at 9-12 hours, and returning to baseline within 24-36 hours[2,3]. CK-MB is an enzyme also present in the cardiac muscle, with a molecular weight of 87.0 kDa[4]. Creatine Kinase is a dimeric molecule formed from two subunits designated as “M” and “B”, which combine to form three different isoenzymes, CK-MM, CK-BB and CK-MB. CK-MB is the isoenzyme of Creatine Kinase most involved in the metabolism of cardiac muscle tissue.[5] The release of CK-MB into the blood following an MI can be detected within 3-8 hours after the onset of symptoms. It peaks within 9 to 30 hours, and returns to baseline levels within 48 to 72 hours[6]. Cardiac Troponin I is a protein found in cardiac muscle, with a molecular weight of 22.5 kDa[7]. Troponin I is part of a three subunit complex comprised of Troponin T and Troponin C. Along with tropomyosin, this structural complex forms the main component that regulates the calcium sensitive ATPase activity of actomyosin in striated skeletal and cardiac muscle[8]. After cardiac injury occurs, Troponin I is released into the blood 4-6 hours after the onset of pain. The release pattern of Troponin I is similar to CK-MB, but while CK-MB levels return to normal after 72 hours, Troponin I remains elevated for 6-10 days, thus providing for a longer window of detection for cardiac injury.

The Myoglobin/CK-MB/Troponin I Combo Test (Whole Blood/Serum/Plasma) utilizes a combination of antibody coated particles and capture reagents to qualitatively detect Myoglobin, CK-MB and Troponin I in whole blood, serum or plasma. The minimum detection level is 50 ng/mL Myoglobin, 5 ng/mL CK-MB and 0.5 ng/mL Troponin I.

PRINCIPLE

The Myoglobin/CK-MB/Troponin I Combo Test (Whole Blood/Serum/Plasma) is a qualitative, membrane based immunoassay for the detection of Myoglobin, CK-MB and Troponin I in whole blood, serum or plasma. The membrane is pre-coated with specific capture antibodies in each of the test line regions of the test. During testing, the whole blood, serum or plasma specimen reacts with the particle coated with specific antibodies. The mixture migrates upward on the membrane chromatographically by capillary action to react with specific capture reagents on the membrane and generate a colored line. The presence of this colored line in the specific test line region indicates a positive result, while its absence indicates a negative result. To serve as a procedural control, a colored line will always appear in the control line region indicating that proper volume of specimen has been added and membrane wicking has occurred.

REAGENTS

The test contains anti-Myoglobin antibody coated particles, anti-CK-MB antibody coated particles, anti-Troponin I antibody coated particles, and capture reagents coated on the membrane.

PRECAUTIONS

- For professional in vitro diagnostic use only. Do not use after expiration date.
- The test must remain in the sealed pouch until use.
- Do not eat, drink or smoke in the area where the specimens or kits are handled.
- Do not use if pouch is damaged.
- Handle all specimens as if they contain infectious agents. Observe established precautions against microbiological hazards throughout the procedure and follow the standard procedures for proper disposal of specimens.
- Wear protective clothing such as laboratory coats, disposable gloves and eye protection when specimens are being tested.
- Humidity and temperature can adversely affect results.
- The used test should be discarded according to local regulations.

STORAGE AND STABILITY

Store as packaged in the sealed pouch either at room temperature or refrigerated (2-30°C). The test is stable through the expiration date printed on the sealed pouch. The test must remain in the sealed pouch until use. Do not freeze. Do not use beyond the expiration date.

SPECIMEN COLLECTION AND STORAGE

- The Myoglobin/CK-MB/Troponin I Combo Test Device (Whole Blood/Serum/Plasma) can be performed using whole blood (from venipuncture or fingerstick), serum or plasma.
- To collect Fingerstick Whole Blood specimens:
  - Wash the patient’s hand with soap and warm water or clean with an alcohol swab. Allow to dry.
  - Massage the hand without touching the puncture site by rubbing down the hand towards the fingertip of the middle or ring finger.
  - Puncture the skin with a sterile lancet. Wipe away the first sign of blood.
  - Gently rub the hand from wrist to palm to finger to form a rounded drop of blood over the puncture site.
  - Position the patient’s finger so that the drop of blood is just above the specimen well (S) of the test device.
  - Allow 2 hanging drops of fingerstick whole blood to fall into the specimen well (S) of the test device, or move the patient’s finger so that the hanging drop touches the specimen well (S). Avoid touching the finger directly to the specimen well (S).
- Separate serum or plasma from blood as soon as possible to avoid hemolysis. Use only clear, non-hemolyzed specimens.
- Testing should be performed immediately after specimen collection. Do not leave the specimens at room temperature for prolonged periods. Serum and plasma specimens may be stored at 2-8°C for up to 3 days. For long-term storage, specimens should be kept below -20°C. Whole blood collected by venipuncture should be stored at 2-8°C if the test is to be run within 2 days of collection. Do not freeze whole blood specimens. Whole blood collected by fingerstick should be tested immediately.
- Bring specimens to room temperature prior to testing. Frozen specimens must be completely thawed and mixed well prior to testing. Specimens should not be frozen and thawed repeatedly.
- If specimens are to be shipped, they should be packed in compliance with local regulations covering the transportation of etiologic agents.

MATERIALS

Materials Provided:1. Test devices 2. Droppers 3. Buffer 4. Desiccant 5. Package insert
Materials Required But Not Provided:1. Specimen collection containers 2. Lancets (for fingerstick whole blood only) 3. Centrifuge 4. Timer

PROCEDURE

Allow the test, specimen and/or controls to reach room temperature (15-30°C) prior to testing.
1. Bring the pouch to room temperature before opening it. Remove the test device from the sealed pouch and use it as soon as possible. Best results will be obtained if the test is performed immediately after opening the foil pouch.
2. Place the test device on a clean and level surface.
For Serum or Plasma specimens: Hold the dropper vertically and transfer 2 drops of serum or plasma (approximately 50 µL) to the specimen well (S) of the test device, then start the timer. See illustration below.
For Venipuncture Whole Blood specimens: Hold the dropper vertically and transfer 2 drops of venipuncture whole blood (approximately 50 µL) to the specimen well (S) of the test device, then add 1 drop of buffer (approximately 40 µL) and start the timer. See illustration below.
For Fingerstick Whole Blood specimens: Allow 2 hanging drops of fingerstick whole blood specimen (approximately 50 µL) to fall into the center of the specimen well (S) on the test device, then add 1 drop of buffer (approximately 40 µL) and start the timer. See illustration below.
3. Wait for the colored line(s) to appear. Read results at 10 minutes. Do not interpret results after 20 minutes.



INTERPRETATION OF RESULTS



(Please refer to the illustration above)

POSITIVE: A colored line in the control line region (C) and the presence of one or more colored lines in the test line regions indicates a positive result. This indicates that the concentration of Myoglobin, CK-MB and/or Troponin I is above the minimum detection level.

NEGATIVE: One colored line appears in the control line region (C). No apparent colored lines appear in any of the test line region(s). This indicates that the concentration of Myoglobin, CK-MB and Troponin I are below the minimum detection levels.

INVALID: Control line (C) fails to appear. Insufficient specimen volume or incorrect procedural techniques are the most likely reasons for control line failure. Review the procedure and repeat the test with a new test. If the problem persists, discontinue using the test kit immediately and contact your local distributor.

QUALITY CONTROL

An internal procedural control is included in the test. A colored line appearing in the control line region (C) is an internal procedural control. It confirms sufficient specimen volume, adequate membrane wicking and correct procedural technique.

Control standards are not supplied with this kit; however it is recommended that positive and negative controls be tested as a good laboratory practice to confirm the test procedure and to verify proper test performance.

LIMITATIONS

1. The Myoglobin/CK-MB/Troponin I Combo Test (Whole Blood/Serum/ Plasma) is for in vitro diagnostic use only. This test should be used for the detection of Myoglobin, CK-MB, and Troponin I in whole blood, serum or plasma specimens only. Neither the quantitative value nor the rate of increase in Myoglobin, CK-MB and Troponin I can be determined by this qualitative test.
2. The Myoglobin/CK-MB/Troponin I Combo Test (Whole Blood/Serum/Plasma) will only indicate the qualitative level of Myoglobin, CK-MB and Troponin I in the specimen and should not be used as the sole criteria for the diagnosis of myocardial infarction.
3. The Myoglobin/CK-MB/Troponin I Combo Test (Whole Blood/Serum/ Plasma) cannot detect less than 50 ng/mL Myoglobin, 5 ng/mL CK-MB and 0.5 ng/mL Troponin I in specimens. A negative result at any time does not preclude the possibility of myocardial infarction.
4. As with all diagnostic tests, all results must be interpreted together with other clinical information available to the physician.
5. Unusually high titers of heterophile antibodies or rheumatoid factor (RF) may affect the results. Even if test results are positive, further clinical evaluation should be considered with other clinical information available to the physician.
6. There is a slight possibility that some whole blood specimens with very high viscosity or which have been stored for more than 2 days may not run properly on the test device. Repeat the test with a serum or plasma specimen from the same patient using a new test device.

EXPECTED VALUES

The Myoglobin/CK-MB/Troponin I Combo Test Device (Whole Blood/Serum/Plasma) has been compared with a leading commercial Myoglobin/CK-MB/T EIA test, demonstrating an overall accuracy of 98.0% with Myoglobin, 99.8% with CK-MB, and 98.5% with Troponin I.

PERFORMANCE CHARACTERISTICS

Sensitivity and Specificity

The Myoglobin/CK-MB/Troponin I Combo Test (Whole Blood/Serum/Plasma) has been evaluated with a leading commercial Myoglobin/CK-MB/Troponin I EIA test using clinical specimens. The results show that relative to leading EIA tests, the Myoglobin/CK-MB/Troponin I Combo Test (Whole Blood/Serum/Plasma) exhibits 100% sensitivity and 97.7% specificity for Myoglobin, 100% sensitivity and 99.8% specificity for CK-MB, and 98.7% sensitivity and 98.4% specificity for Troponin I.

Myoglobin Test vs. EIA

Method		EIA		Total
	Results	Positive	Negative	Results
Myoglobin Test	Positive	60	9	69
	Negative	0	374	374
Total Results		60	383	443

Relative Sensitivity: 100% (94.0%-100.0%)*
Relative Specificity: 97.7% (95.6%-98.9%)*
Accuracy: 98.0% (96.2%-99.1%)*
* 95% Confidence Interval

CK-MB Test vs. EIA

Method		EIA		Total
	Results	Positive	Negative	Results
CK-MB Test	Positive	54	1	55
	Negative	0	422	422
Total Results		54	423	477

Relative Sensitivity: 100% (93.4%-100.0%)*
Relative Specificity: 99.8% (98.7%-99.9%)*
Accuracy: 99.8% (98.8%-99.9%)*
* 95% Confidence Interval

Troponin I Test vs. EIA

Method		EIA		Total
	Results	Positive	Negative	Results
Troponin I Test	Positive	225	8	233
	Negative	3	505	508
Total Results		228	513	741

Relative Sensitivity: 98.7% (96.2%-99.7%)*
Relative Specificity: 98.4% (97.0%-99.3%)*
Accuracy: 98.5% (97.4%-99.3%)*
* 95% Confidence Interval

Precision

Intra-Assay

Within-run precision has been determined by using replicates of 10 tests for each of three lots using Myoglobin specimen levels at 0 ng/mL, 50 ng/mL and 400 ng/mL, CK-MB specimen levels at 0 ng/mL, 5 ng/mL and 40 ng/mL and Troponin I specimen levels at 0 ng/mL, 1 ng/mL and 10 ng/mL. The specimens were correctly identified >99% of the time.

Inter-Assay

Between-run precision has been determined by 3 independent assays on the same fifteen specimens: 0 ng/mL, 50 ng/mL and 400 ng/mL of Myoglobin, 0 ng/mL, 5 ng/mL and 40 ng/mL of CK-MB and 0 ng/mL, 1 ng/mL and 10 ng/mL of Troponin I. Three different lots of the Myoglobin/CK-MB/ Troponin I Combo Test Device (Whole Blood/Serum/Plasma) have been tested using these specimens. The specimens were correctly identified >99% of the time.

Cross-Reactivity

Sera containing known amounts of 10,000 ng/mL Skeletal Troponin I, 2,000 ng/mL Troponin T, 1,390 ng/mL CK-MM, 1,000 ng/mL CK-BB and 20,000 ng/mL Cardiac Myosin have been tested. No cross-reactivity was observed, indicating that the Myoglobin/CK-MB/Troponin I Combo Test Device (Whole Blood/ Serum/Plasma) has a high degree of specificity for Myoglobin, CK-MB and Troponin I.

Interfering Substances

The Myoglobin/CK-MB/Troponin I Combo Test Device (Whole Blood/Serum/Plasma) has been tested and no interference was observed in specimens containing 110 mg/mL human albumin, 6 mg/mL bilirubin, 10 mg/mL hemoglobin, 5 mg/mL cholesterol and 15 mg/mL triglycerides.

BIBLIOGRAPHY

1. Wong SS. Strategic utilization of cardiac markers for diagnosis of acute myocardial infarction. Ann Clin Lab Sci, 26:301-12, 1996.
2. Kagen LJ. Myoglobin methods and diagnostic uses. CRC Crit. Rev. Clin. Lab. Sci., 2:273, 1978.
3. Chapelle JP. et al. Serum myoglobin determinations in the assessment of acute myocardial infarction. Eur. Heart Journal, 3:122, 1982.
4. Apple FS, Preese LM. Creatine kinase-MB: detection of myocardial infarction and monitoring reperfusion. J Clin Immunoassay, 17:24-9, 1994.
5. Lee TH, Goldman L. Serum enzyme assays in the diagnosis of acute myocardial infarction. Ann Intern Med, 105:221-233, 1986.
6. Kallner A, Sylven C, Brodin. U, et al. Early diagnosis of acute myocardial infarction; a comparison between chemical predictors. Scand J Clin Lab Invest, 49:633-9, 1989.
7. Adams, et al. Biochemical markers of myocardial injury, Immunoassay Circulation 88: 750-763, 1993.
8. Mehegan JP, Tobacman LS. Cooperative interaction between troponin molecules bound to the cardiac thin filament. J.Biol.Chem. 266:966, 1991.

Getein Biotech, Inc.
Add: No.9 Bofu Road, Luhe District, Nanjing, 211505, China
Tel: 86-25-68568508 Email: overseas@getein.com.cn Web: www.getein.com

Document No.: GP-GMSQ-2023121301

Letter of Authorization

To whom it may concern,

We, **Getein Biotech, Inc.** (No.9 Bofu Road, Luhe District, Nanjing, 211505, China), hereby authorize Sanmedico SRL (Address: Republic of Moldova, Chisinau, MD-2059, Petricani street, 88/1, office 10) as our official and non-exclusive distributor for registration, promoting, selling, distributing and providing after-sale services of under-mentioned product in the territory of Moldova only:

FIA8000 Quantitative Immunoassay Analyzer and Reagents

Getein1100 Immunofluorescence Quantitative Analyzer and Reagents

Getein1160 Immunofluorescence Quantitative Analyzer and Reagents

Getein 1600 Immunofluorescence Quantitative Analyzer and Reagents

Sanmedico SRL will comply with the laws and regulations of the countries and regions where they are located in and where they are selling mentioned product.

Sanmedico SRL will carry out marketing efforts to fulfill service and maintenance for above mentioned products and will provide with users benefits of having a local stock of above mentioned products and on-time delivery with every order, supported by a local service in local language.

This authorization starts from **1st Jan, 2024** and will be valid to **31th, December, 2024** .

Getein Biotech, Inc. has the right to terminate the authorization before validity and will inform Sanmedico SRL with 10 days in advance.

基蛋生物科技股份有限公司
GETEIN BIOTECH, INC.

Getein Biotech, Inc.
Seal & Signature

Authority Person Name: **Steven Zhou**
Authority Person Position: **Regional Manager**
Date: **2023.12.13**

EC Declaration of Conformity

according to Directive 98/79/EC, on in vitro diagnostic medical devices

Ref. No.:20220513-F02

Manufacturer
(Name, Address)

Getein Biotech, Inc.
No. 9 Bofu Road, Luhe District, Nanjing, 211505, China

Authorized Representative
(Name, Address)

CMC Medical Devices & Drugs S.L.
Add: C/ Horacio Lengo Nº 18, CP 29006, Málaga, Spain

Medical device

No.	**Product Name**
1	Myo Control
2	CK-MB Control
3	NT-proBNP Control
4	D-Dimer Control
5	PCT Control
6	CRP Control
7	cTnI Control
8	H-FABP Control
9	mAlb Control
10	NGAL Control
11	β_2-MG Control
12	CysC Control
13	CK-MB/cTnI/Myo Control
14	CK-MB/cTnI Control
15	NT-proBNP/cTnI Control
16	HCG+β Control
17	HbA1c Control
18	TSH Control
19	T4 /T3 Control
20	T3 Control
21	T4 Control

22	FOB Control
23	H. pylori Control
24	SAA Control
25	LH Control
26	FSH Control
27	25-OH-VD Control
28	fT3 Control
29	fT4 Control
30	PRL Control
31	SARS-CoV-2 Control
32	Prog Control
33	IL-6 Control
34	Fer Control
35	cTnT Control
36	BNP Control
37	IGE Control
38	AMH Control
39	TPO Control
40	TG-Ab Control
41	T Control
42	E2 Control
43	E3 Control
44	HCG+β Control
45	CA50 Control
46	CA125 Control
47	CA15-3 Control
48	CA19-9 Control
49	CA242 Control
50	CA72-4 Control
51	CY21-1 Control
52	NSE Control

53	AFP Control
54	CEA Control
55	Fer Control
56	HE4 Control
57	cTnT Control
58	INS Control
59	C-P Control
60	PTH Control
61	BGP Control
62	IAA Control
63	IgE Control
64	GH Control
65	Cor Control
66	TP Control
67	PGI Control
68	PGII Control
69	G17 Control
70	Pro-GRP Control
71	SCC Control
72	ST2 Control
73	PLA2 Control
74	CG Control
70	HA Control
71	LN Control
72	III Control
73	CIV Control
74	SHBG Control
75	Renin Control
76	TG Control
77	PVK Control
78	HBP Control

79	PIIIP N-P Control
80	CIV Control
81	CRP Calibrator
82	β2-MG Calibrator
83	C3 Calibrator
84	C4 Calibrator
85	IgA Calibrator
86	CysC Calibrator
87	IgG Calibrator
88	IgM Calibrator
89	PA Calibrator
90	ApoA1 Calibrator
91	ApoB Calibrator

Classification	Other device (according to Annex II of the directive 98/79/EC)		
Conformity assessment route	Annex III of the 98/79/EC		
Applicable coordination standards	EN 13612:2002	EN ISO 14971:2019	EN ISO15223-1:2016
	EN ISO 18113-1:2011	EN ISO 18113-2:2011	EN ISO 18113-3:2011
	EN ISO 23640:2015	EN ISO 13485:2016	ISO 780:2015

Signatory representative declares herein the above-mentioned device meets the basic requirements of the European Parliament and the Council's in vitro diagnostic medical devices directive: 98/79/EC Annex I.

This declaration of conformity is based on European Parliament and the Council's 98/79/EC directive Annex III. The compiled technical file and quality system document according to 98/79/EC directive Annex III are testified and the quality system certificate has issued by BSI Group The Netherlands B. V. The manufacturer is exclusively responsible for the declaration of conformity.

General Manager Enben Su

Nanjing, 13th may 2022

(place and date of issue)

Enben Su

(name and signature or equivalent marking of authorized person)

CE

EC Declaration of Conformity

according to Directive 98/79/EC, on in vitro diagnostic medical devices

Ref. No.:20220513-A05

Manufacturer
(Name, Address)

Getein Biotech, Inc.
No. 9 Bofu Road, Luhe District, Nanjing, 211505, China

Authorized Representative
(Name, Address）

CMC Medical Devices & Drugs S.L.
Add: C/ Horacio Lengo Nº 18, CP 29006, Málaga, Spain

Medical device

No.	Product Name
1	Getein 1100 Immunofluorescence Quantitative Analyzer
2	Cardiac Troponin I Fast Test Kit (Immunofluorescence Assay)
3	NT-proBNP Fast Test Kit (Immunofluorescence Assay)
4	hs-CRP+CRP Fast Test Kit (Immunofluorescence Assay)
5	NT-proBNP/cTnI Fast Test Kit (Immunofluorescence Assay)
6	CK-MB/cTnI/Myo Fast Test Kit (Immunofluorescence Assay)
7	D-Dimer Fast Test Kit (Immunofluorescence Assay)
8	PCT Fast Test Kit (Immunofluorescence Assay)
9	CysC Fast Test Kit (Immunofluorescence Assay)
10	mAlb Fast Test Kit (Immunofluorescence Assay)
11	NGAL Fast Test Kit (Immunofluorescence Assay)
12	β2-MG Fast Test Kit (Immunofluorescence Assay)
13	CK-MB/cTnI Fast Test Kit (Immunofluorescence Assay)
14	HCG+β Fast Test Kit (Immunofluorescence Assay)
15	H-FABP Fast Test Kit (Immunofluorescence Assay)
16	PCT/CRP Fast Test Kit (Immunofluorescence Assay)
17	CK-MB/cTnI/H-FABP Fast Test Kit (Immunofluorescence Assay)
18	HbA1c Fast Test Kit (Immunofluorescence Assay)
19	NT-proBNP/NGAL Fast Test Kit (Immunofluorescence Assay)
20	CK-MB Fast Test Kit (Immunofluorescence Assay)
21	hs-cTnI Fast Test Kit (Immunofluorescence Assay)
22	T3 Fast Test Kit (Immunofluorescence Assay)
23	T4 Fast Test Kit (Immunofluorescence Assay)
24	TSH Fast Test Kit (Immunofluorescence Assay)
25	Scr Fast Test Kit (Immunofluorescence Assay)
26	PLGF Fast Test Kit (Immunofluorescence Assay)

27	HCY Fast Test Kit (Immunofluorescence Assay)
28	Anti-CCP Fast Test Kit (Immunofluorescence Assay)
29	25-OH-VD Fast Test Kit (Immunofluorescence Assay)
30	Lp-PLA2 Fast Test Kit (Immunofluorescence Assay)
31	FOB Fast Test Kit (Immunofluorescence Assay)
32	SAA Fast Test Kit (Immunofluorescence Assay)
33	H. pylori Fast Test Kit (Immunofluorescence Assay)
34	PRL Fast Test Kit (Immunofluorescence Assay)
35	Transferrin Fast Test Kit (Immunofluorescence Assay)
36	Insulin Fast Test Kit (Immunofluorescence Assay)
37	PG Ⅰ /PG Ⅱ Fast Test Kit (Immunofluorescence Assay)
38	LH Fast Test Kit (Immunofluorescence Assay)
39	FSH Fast Test Kit (Immunofluorescence Assay)
40	Anti-TP Fast Test Kit (Immunofluorescence Assay)
41	AFP/CEA Fast Test Kit (Immunofluorescence Assay)
42	AMH Fast Test Kit (Immunofluorescence Assay)
43	fT3 Fast Test Kit (Immunofluorescence Assay)
44	fT4 Fast Test Kit (Immunofluorescence Assay)
45	Total IgE Fast Test Kit (Immunofluorescence Assay)
46	Vit-B12 Fast Test Kit (Immunofluorescence Assay)
47	Prog Fast Test Kit (Immunofluorescence Assay)
48	Testosterone Fast Test Kit (Immunofluorescence Assay)
49	E2 Fast Test Kit (Immunofluorescence Assay)
50	RF Fast Test Kit (Immunofluorescence Assay)
51	ASO Fast Test Kit (Immunofluorescence Assay)
52	Ferritin Fast Test Kit (Immunofluorescence Assay)
53	ST2 Fast Test Kit (Immunofluorescence Assay)
54	CA125 Fast Test Kit (Immunofluorescence Assay)
55	CA19-9 Fast Test Kit (Immunofluorescence Assay)
56	CA15-3 Fast Test Kit (Immunofluorescence Assay)
57	RSV/Influenza A/B Fast Test Kit (Immunofluorescence Assay)
58	Influenza A/B Fast Test Kit (Immunofluorescence Assay)
59	RSV Fast Test Kit (Immunofluorescence Assay)
60	IL-6 Fast Test Kit (Immunofluorescence Assay)
61	BNP Fast Test Kit (Immunofluorescence Assay)
62	SAA/CRP Fast Test Kit (Immunofluorescence Assay)
63	Folate acid Fast Test Kit (Immunofluorescence Assay)
64	hs-CRP Fast Test Kit (Immunofluorescence Assay)
65	TnT Fast Test Kit (Immunofluorescence Assay)
66	PCT/IL-6 Fast Test Kit (Immunofluorescence Assay)

67	HBP Fast Test Kit (Immunofluorescence Assay)
68	S100-β Fast Test Kit (Immunofluorescence Assay)
69	CK-MB/hs-cTnI/Myo Fast Test Kit (Immunofluorescence Assay)
70	Cortisol Fast Test Kit (Immunofluorescence Assay)
71	CEA Fast Test Kit (Immunofluorescence Assay)
72	AFP/CEA Fast Test Kit (Immunofluorescence Assay)

Classification Other device (according to Annex II of the directive 98/79/EC)

Conformity assessment route Annex III of the 98/79/EC

Applicable coordination standards

EN 13612:2002	EN ISO 14971:2019	EN ISO15223-1:2016
EN ISO 18113-1:2011	EN ISO 18113-2:2011	EN ISO 18113-3:2011
EN ISO 23640:2015	EN ISO 13485:2016	ISO 780:2015
EN 61326-2-6:2006	IEC 61326-1:2013	
EN 61010-2-101:2002	IEC 61010-1:2010	

Signatory representative declares herein the above-mentioned device meets the basic requirements of the European Parliament and the Council's in vitro diagnostic medical devices directive: 98/79/EC Annex I.

This declaration of conformity is based on European Parliament and the Council's 98/79/EC directive Annex III. The compiled technical file and quality system document according to 98/79/EC directive Annex III are testified and the quality system certificate has issued by BSI Group The Netherlands B. V. The manufacturer is exclusively responsible for the declaration of conformity.

General Manager Enben Su

Nanjing
13th, May, 2022
(place and date of issue)

Enben Su
(name and signature or equivalent marking of authorized person)

CE

Declaration of Conformity

according to Directive 98/79/EC, on in vitro diagnostic medical devices

Maker (Name, Address)	**Getein Biotech, Inc.** No. 9 Bofu Road, Luhe District, Nanjing, 211505, China		
Authorized Representative (Name, Address)	**Lotus NL B.V.** Koningin Julianaplein 10, 1e Verd, 2595AA, The Hague, Netherlands.		
Medical device	Description	:	FIA8000 Quantitative Immunoassay Analyzer FIA8600 Quantitative Immunoassay Analyzer Cardiac Troponin I Fast Test Kit One Step Test for cTnI (Colloidal Gold) cTnI Rapid Test (Colloidal Gold Assay) One Step Test for NT-proBNP (Colloidal Gold) One Step Test for NT-proBNP/cTnI (Colloidal Gold) One Step Test for CK-MB/cTnI/Myo (Colloidal Gold) One Step Test for hs-CRP+CRP (Colloidal Gold) One Step Test for D-Dimer (Colloidal Gold) One Step Test for PCT (Colloidal Gold) One Step Test for β2-MG (Colloidal Gold) One Step Test for mAlb (Colloidal Gold) One Step Test for NGAL (Colloidal Gold) One Step Test for CysC (Colloidal Gold) One Step Test for HCG+β (Colloidal Gold) One Step Test for HbA1c (Colloidal Gold) One Step Test for PCT/CRP (Colloidal Gold) One Step Test for CK-MB/cTnI/H-FABP (Colloidal Gold) One Step Test for H-FABP (Colloidal Gold) One Step Test for CK-MB/cTnI (Colloidal Gold) One Step Test for CK-MB (Colloidal Gold) One Step Test for TSH (Colloidal Gold) One Step Test for T4/T3 (Colloidal Gold) One Step Test for T3 (Colloidal Gold) One Step Test for T4 (Colloidal Gold) One Step Test for 25-OH-VD (Colloidal Gold) One Step Test for FOB (Colloidal Gold) One Step Test for *H. pylori* (Colloidal Gold) One Step Test for SAA (Colloidal Gold) Getein1100 Immunofluorescence Quantitative Analyzer Getein1600 Immunofluorescence Quantitative Analyzer Getein1180 Immunofluorescence Quantitative Analyzer Getein1200 Immunofluorescence Quantitative Analyzer Cardiac Troponin I Fast Test Kit (Immunofluorescence Assay) NT-proBNP Fast Test Kit (Immunofluorescence Assay) hs-CRP+CRP Fast Test Kit (Immunofluorescence Assay) NT-proBNP/cTnI Fast Test Kit (Immunofluorescence Assay) CK-MB/cTnI/Myo Fast Test Kit (Immunofluorescence Assay) D-Dimer Fast Test Kit (Immunofluorescence Assay)

			PCT Fast Test Kit (Immunofluorescence Assay) β2-MG Fast Test Kit (Immunofluorescence Assay) mAlb Fast Test Kit (Immunofluorescence Assay) NGAL Fast Test Kit (Immunofluorescence Assay) CysC Fast Test Kit (Immunofluorescence Assay) CK-MB Fast Test Kit (Immunofluorescence Assay) CK-MB/cTnI Fast Test Kit (Immunofluorescence Assay) HCG+β Fast Test Kit (Immunofluorescence Assay) HbA1c Fast Test Kit (Immunofluorescence Assay) PCT/CRP Fast Test Kit (Immunofluorescence Assay) CK-MB/cTnI/H-FABP Fast Test Kit (Immunofluorescence Assay) H-FABP Fast Test Kit (Immunofluorescence Assay) 25-OH-VD Fast Test Kit (Immunofluorescence Assay) TSH Fast Test Kit (Immunofluorescence Assay) T3 Fast Test Kit (Immunofluorescence Assay) T4 Fast Test Kit (Immunofluorescence Assay 25-OH-VD Fast Test Kit (Immunofluorescence Assay) FOB Fast Test Kit (Immunofluorescence Assay) *H. pylori* Fast Test Kit (Immunofluorescence Assay) SAA Fast Test Kit (Immunofluorescence Assay) LH Fast Test Kit (Immunofluorescence Assay) FSH Fast Test Kit (Immunofluorescence Assay) AMH Fast Test Kit (Immunofluorescence Assay) PRL Fast Test Kit (Immunofluorescence Assay) CK-MB Control cTnI Control Myo Control NT-proBNP Control D-Dimer Control CRP Control PCT Control β2-MG Control mAlb Control NGAL Control CysC Control H-FABP Control HbA1c Control HCG+β Control CK-MB/cTnI/Myo Control CK-MB/cTnI Control NT-proBNP/cTnI Control TSH Control T4/T3 Control T3 Control T4 Control
	Classification of products according to directive	:	Others
	Batch/serial No. Type, production term (if applicable)	:	

Applicable coordination standards:	EN ISO 14971:2012 EN 13612:2002 EN 1041:2008 IEC 61010-1:2010 IEC 61326-1:2013	EN ISO 23640:2015 EN ISO15223-1:2012 EN ISO 18113-1:2011 IEC 61010-2-081:2015 IEC 61326-2-2:2013	EN ISO 13485:2016 EN ISO 18113-2:2011 EN ISO 18113-3:2011 IEC 61010-2-101:2015

Signatory representative declares herein the above mentioned device meets the basic requirements of the European Parliament and the Council's in vitro diagnostic medical devices directive: 98/79/EC Annex III. This declaration of conformity is based on European Parliament and the Council's 98/79/EC directive Annex III. The compiled technical file and quality system document according to 98/79/EC directive Annex III are testified and the quality system certificate has issued by TÜV Rheinland (Shanghai) Co., Ltd.

General Manager: Enben Su

Nanjing, 20th, Jul, 2019

(place and date of issue)

(name and signature or equivalent marking of authorized person)

By Royal Charter

Certificate of Registration

QUALITY MANAGEMENT SYSTEM - ISO 13485:2016

This is to certify that:

Getein Biotech, Inc.
No.9 Bofu Road
Luhe District
Nanjing
Jiangsu
211505
China

基蛋生物科技股份有限公司
中国
江苏省
南京市
六合区
沿江工业开发区
博富路9号
邮编：211505

Holds Certificate No: **MD 728432**

and operates a Quality Management System which complies with the requirements of ISO 13485:2016 for the following scope:

Please see scope page.

For and on behalf of BSI:

Graeme Tunbridge, Senior Vice President Medical Devices

Original Registration Date: 2020-05-29
Latest Revision Date: 2023-04-26

Effective Date: 2023-07-26
Expiry Date: 2026-07-25

...making excellence a habit.™

Certificate No: **MD 728432**

Registered Scope:

Design & Development, Manufacture and Distribution of Chemiluminescence Immunoassay, Biochemistry Assay, Point of Care Assay (including Colloidal Gold Assay, Immunofluorescence Assay, Dry Chemistry Assay), PCR Assay and Colloidal Gold self-testing Assay to detect infectious disease. Design & Development, Manufacture and Distribution of Analyzers in use of Chemiluminescence Immunoassay, Biochemistry Assay, Point of Care Assay (including Colloidal Gold Assay, Immunofluorescence Assay, Dry Chemistry Assay), PCR Assay to detect infectious disease, Immunofluorescence self-testing Assay to detect dyslipidemia disease, Blood Coagulation Assay to detect thrombotic disease.
研发，生产和销售化学发光法试剂，生化试剂，即时诊断（包括胶体金法，免疫荧光法，干式化学法）试剂，传染病相关PCR分子诊断试剂和胶体金自测试剂。 研发，生产和销售用于化学发光法试剂，生化试剂，即时诊断（包括胶体金法，免疫荧光法，干式化学法）试剂，传染病相关PCR分子诊断试剂，血脂异常疾病相关免疫荧光自测试剂，血栓疾病相关血凝试剂配套使用的分析仪。

Original Registration Date: 2020-05-29
Latest Revision Date: 2023-04-26

Effective Date: 2023-07-26
Expiry Date: 2026-07-25

Certificate No: **MD 728432**

Location	Registered Activities
Getein Biotech, Inc. No.9 Bofu Road Luhe District Nanjing Jiangsu 211505 China 基蛋生物科技股份有限公司 中国 江苏省 南京市 六合区 沿江工业开发区 博富路9号 邮编：211505	Design & Development, Manufacture and Distribution of Chemiluminescence Immunoassay, Biochemistry Assay, Point of Care Assay (including Colloidal Gold Assay, Immunofluorescence Assay, Dry Chemistry Assay), PCR Assay and Colloidal Gold self-testing Assay to detect infectious disease. Design & Development, Manufacture and Distribution of Analyzers in use of Chemiluminescence Immunoassay, Biochemistry Assay, Point of Care Assay (including Colloidal Gold Assay, Immunofluorescence Assay, Dry Chemistry Assay), PCR Assay to detect infectious disease, Immunofluorescence self-testing Assay to detect dyslipidemia disease, Blood Coagulation Assay to detect thrombotic disease. 研发，生产和销售化学发光法试剂，生化试剂，即时诊断（包括胶体金法，免疫荧光法，干式化学法）试剂，传染病相关PCR分子诊断试剂和胶体金自测试剂。 研发，生产和销售用于化学发光法试剂，生化试剂，即时诊断（包括胶体金法，免疫荧光法，干式化学法）试剂，传染病相关PCR分子诊断试剂，血脂异常疾病相关免疫荧光自测试剂，血栓疾病相关血凝试剂配套使用的分析仪。
Getein Biotech, Inc. No. 6 KeFeng Road Jiangbei New District Nanjing Jiangsu 211505 China 基蛋生物科技股份有限公司 中国 江苏省 南京 江北新区 科丰路6号 邮编：211505	Manufacture of Chemiluminescence Immunoassay, Biochemistry Assay, Point of Care Assay (including Colloidal Gold Assay, Immunofluorescence Assay, Dry Chemistry Assay), Colloidal Gold self-testing Assay to detect infectious disease. Manufacture of Analyzers in use of Chemiluminescence Immunoassay, Biochemistry Assay, Point of Care Assay (including Colloidal Gold Assay, Immunofluorescence Assay, Dry Chemistry Assay), PCR Assay to detect infectious disease, Immunofluorescence self-testing Assay to detect dyslipidemia disease, Blood Coagulation Assay to detect thrombotic disease. 生产化学发光法试剂，生化试剂，即时诊断（包括胶体金法，免疫荧光法，干式化学法）试剂和传染病相关胶体金自测试剂。 生产用于化学发光法试剂，生化试剂，即时诊断（包括胶体金法，免疫荧光法，干式化学法）试剂，传染病相关PCR分子诊断试剂，血脂异常疾病相关免疫荧光自测试剂，血栓疾病相关血凝试剂配套使用的分析仪。

Original Registration Date: 2020-05-29

Effective Date: 2023-07-26

Latest Revision Date: 2023-04-26

Expiry Date: 2026-07-25

Reference Code：GP-DT-018-07-19 Issued by 07/26/2019

CERTIFICATE

Getein Biotech

hereby certifies

Mr. Vitalie Goreacii

from Sanmedico SRL.

Completion of Getein Products Technical and Operational Training
& Qualification of After-sales Service

基蛋生物科技股份有限公司
GETEIN BIOTECH, INC.

Getein
Biotech, Inc.

CE IVD

CK-MB

Fast Test Kit

(Immunofluorescence Assay)
For in vitro Diagnostic Use

User Manual

Getein1100: Cat.# IF1018
Getein1600: Cat.# IF2018

INTENDED USE

CK-MB Fast Test Kit (Immunofluorescence Assay) is intended for in vitro quantitative determination of CK-MB in serum, plasma or whole blood. This test is used as an aid in the clinical diagnosis, prognosis and evaluation of myocardial injury such as Acute Myocardial Infarction (AMI), Unstable Angina, Acute Myocarditis and Acute Coronary Syndrome (ACS).

SUMMARY

Creatine kinases are dimer isozymes composed of two monomer subunits, CK-M (for skeletal muscle derived) and CK-B (for brain derived), which can form all three combinations of monomers: CK-BB, CK-MM, and CK-MB. BB is found primarily in the brain. Skeletal muscles primarily contain the MM isoform, with trace amount of MB (around 1-4% of total CK activity). Cardiac muscles also contain the MM isoform, but higher amount of MB, typically around 20% of total CK activity. CK-MB is a more sensitive marker of myocardial injury than total CK activity, because it has a lower basal level and a much narrower normal range. Medical literatures commonly state that CK-MB levels are elevated in 4 to 6 hours, peak at 10 to 24 hours, and return to normal within 3 to 4 days after an acute myocardial infarction. Classically, an increase of the myocardial-specific enzyme CK-MB is considered as the hallmark of acute myocardial infarction, and increased levels are frequently interpreted by the clinician as objective evidence of myocardial cell damage.

PRINCIPLE

Monoclonal antibody against human CK-MB were conjugated with fluorescence latex and another set of anti-human CK-MB monoclonal antibodies were coated on test line. After the sample has been applied to the test strip, the latex-labeled anti-human CK-MB monoclonal antibody will bind with the CK-MB in sample and form marked antigen-antibody complex. This complex move to the test card detection zone by capillary action. Then marked antigen-antibody complex will be captured on test line by another set of monoclonal antibody against human CK-MB resulting in purplish red streaks appear on the test line. The color intensity of test line increases in proportion to the amount of CK-MB in sample.

Insert test card into Getein1100 Immunofluorescence Quantitative Analyzer/Getein1600 Immunofluorescence Quantitative Analyzer (hereafter referred to as Getein1100 and Getein1600), the concentrations of CK-MB in sample will be determined and displayed on the screen. The value will be stored in Getein1100/Getein1600 and available for downloading. The result can be easily transmitted to LIS and HIS.

CONTENTS

1.A kit for Getein1100 contains:

Getein CK-MB test card in a sealed pouch with desiccant.....25
Disposable pipet.....25
User manual 1
SD card/ RFID card 1
Whole blood buffer.....1

2.A kit for Getein1600 contains:

Sealed cartridge with 24/48 Getein CK-MB test cards 2
User manual 1
Package specifications:
2×24 tests/kit, 2×48 tests/kit
Materials required for Getein1600:
Sample diluent.....1
Box with pipette tips 1
Mixing plate.....1

3.Sample diluent/Whole blood buffer composition:

Phosphate buffered saline, proteins, detergent, preservative, stabilizer.

4.A test card consists of:

A plastic shell and a reagent strip which is composed of a sample pad, a colloidal gold pad (coated with fluorescence latex-labeled anti-human CK-MB monoclonal antibodies), nitrocellulose membrane with test line (the test line is coated with another anti-human CK-MB monoclonal antibody, and the control line is coated with rabbit anti-mouse IgG antibody), absorbent paper and liner.

Note:Do not mix or interchange different batches of kits.

APPLICABLE DEVICE

Getein1100 Immunofluorescence Quantitative Analyzer
Getein1600 Immunofluorescence Quantitative Analyzer

STORAGE AND STABILITY

Store the test card at 4~30℃ with a valid period of 24 months.
Use the test card for Getein1100 within 1 hour once the foil pouch is opened.
Use the test card for Getein1600 within 24 hours once opened.
Store the sample diluent/whole blood buffer at 0~30℃ with a valid period of 24 months.
Store the sample diluent/whole blood buffer at 2~8℃ for better results.

PRECAUTIONS

1.For in vitro diagnostic use only.
2.For professional use only.
3.Do not use the kit beyond the expiration date.
4.Do not use the test card if the foil pouch or the cartridge is damaged.
5.Do not open pouches or the cartridge until ready to perform the test.
6.Do not reuse the test card.
7.Do not reuse the pipet.
8.Handle all specimens as potentially infectious. Proper handling and disposal methods should be followed in accordance with local regulations.
9.Carefully read and follow user manual to ensure proper test performance.

SPECIMEN COLLECTION AND PREPARATION

1.This test can be used for ***serum, plasma and whole blood*** samples.***Heparin and sodium citrate*** can be used as the anticoagulant for plasma and whole blood. Samples should be free of hemolysis.
2.Suggest using serum or plasma for better results.
3.Serum or plasma can be used directly. For whole blood sample, one drop of whole blood buffer must be added before testing.

4.If testing will be delayed, serum and plasma samples may be stored up to 7 days at 2~8℃ or stored at -20℃ for 6 months before testing (whole blood sample may be stored up to 3 days at 2~8℃).
5.Refrigerated or frozen sample should reach room temperature and be homogeneous before testing. Avoid multiple freeze-thaw cycles.
6.Do not use heat-inactivated samples.
7.***SAMPLE VOLUME (for Getein1100): 100 µl.***

TEST PROCEDURE

1.Collect specimens according to user manual.
2.Test card, sample and reagent should be brought to room temperature before testing.

For Getein1100:

3.Confirm SD card or RFID card lot No. in accordance with test kit lot No.. Perform "SD card or RFID card Calib" calibration when necessary.
4.Enter testing interface of Getein1100.
5.Remove the test card from the sealed pouch immediately before use. Label the test card with patient or control identification.
6.Put the test card on a clean table, horizontally placed.
7.Using sample transfer pipette, deliver 100 µl of sample (or 3~4 drops of sample when using disposable pipet) into the sample port on the test card (for whole blood sample, one drop of whole blood buffer must be added after loading 100 µl sample on the test card).
8.***Reaction time: 10 minutes.*** Insert the test card into Getein1100 and start test after reaction time is elapsed. The result will be shown on the screen and printed automatically.

For Getein1600:

9.Each cartridge for Getein1600 contains a specific RFID card which can calibrate automatically.
10.Place samples in the designed area of the sample holder, insert the holder and select the right test item, Getein1600 will do the testing and print the result automatically.

Notes:

1.It is required to perform "SD Card or RFID card Calib" calibration when using a new batch of kits.
2.It is suggested to calibrate once for one batch of kits for Getein1100.
3.Make sure the test card insertion is correct and complete.

TEST RESULTS

Getein1100/Getein1600 can scan the test card automatically and display the result on the screen. For additional information, please refer to the user manual of Getein1100/Getein1600.

EXPECTED VALUE

The expected normal value for CK-MB was determined by testing samples from 500 apparently healthy individuals. The 99th percentile of the concentration for CK-MB is 5.0 ng/ml. CK-MB concentration less than 5.0 ng/ml can be estimated as normal.
It is recommended that each laboratory establish its own expected values for the population it serves.

PERFORMANCE CHARACTERISTICS

Measuring Range	2.5~80.0 ng/ml
Lower Detection Limit	≤ 2.5ng/ml
Within-Run Precision (n=10)	≤10%
Between-Run Precision	≤15%

Method Comparison:

The assay was compared with ROCHE E170 and its matching CK-MB test kits with 200 serum samples. The correlation coefficient (r) for CK-MB is 0.982.

LIMITATIONS

1.As with all diagnostic tests, a definitive clinical diagnosis should not be made based on the result of a single test. The test results should be interpreted considering all other test results and clinical information such as clinical signs and symptoms.
2.Samples containing interferents may influence the results. The table below listed the maximum allowance of these potential interferents.

Interferent	Hemoglobin	Triglyceride	Bilirubin
Concentration (Max)	5 g/L	10 g/L	0.2 g/L

REFERENCES

1.Mauro Pantaghini; Undefined International Federation of Clinical Chemistry and Laboratory Medicine (IFCC) Scientific Division Committee on Standardization of Markers of Cardiac Damage. Clin Chem Lab Med, 1998, 36:887~893.
2.Antman EM, Anbe DT, Armstrong PW, et al. ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Revise the 1999 Guidelines for the Manage 2004).
3.EN ISO 18113-1:2011 In vitro diagnostic medical devices - Information supplied by the manufacturer (labeling) - Part 1: Terms, definitions and general requirements.
4.EN ISO 18113-2:2011 In vitro diagnostic medical devices - Information supplied by the manufacturer (labeling) - Part 2: In vitro diagnostic reagents for professional use (ISO18113-2:2011).

DESCRIPTION OF SYMBOLS USED

The following graphical symbols used in or found on CK-MB Fast Test Kit (Immunofluorescence Assay) are the most common ones appearing on medical devices and their packaging. They are explained in more details in the European Standard EN 980:2008 and International Standard ISO 15223-1:2012.

Key to symbols used			
	Manufacturer		Expiration date
	Do not reuse		Date of manufacture
	Consult instructions for use	LOT	Batch code
	Temperature limitation	IVD	*In vitro* diagnostic medical device
	Sufficient for	EC REP	Authorized representative in the European Community
CE	CE mark		Do not use if package is damaged

Thank you for purchasing CK-MB Fast Test Kit (Immunofluorescence Assay).
Please read this user manual carefully before operating to ensure proper use.

Version: WIF28-S-01

Getein Biotech, Inc.
Add: No.9 Bofu Road, Luhe District, Nanjing, 211505, China
Tel: +86-25-68568508 Fax: +86-25-68568500
E-mail:tech@getein.com.cn overseas@getein.com.cn
Website: www.bio-GP.com.cn

Cardiac Troponin I
Fast Test Kit
(Immunofluorescence Assay)

User Manual

Getein1100: Cat.# IF1001
Getein1600: Cat.# IF2001

INTENDED USE

Cardiac Troponin I Fast Test Kit (Immunofluorescence Assay) is intended for *in vitro* quantitative determination of Cardiac Troponin I (cTnI) in serum, plasma or whole blood. This test is used as an aid in the diagnosis of myocardial injury such as Acute Myocardial Infarction (AMI), Unstable Angina, Acute Myocarditis and Acute Coronary Syndrome (ACS).

SUMMARY

Troponin, a molecular complex that is bound to the thin filament (actin) of striated muscle fibers, acts with intracellular calcium to control the interaction of the thin filament with the thick filament (myosin), thus regulating muscle contraction. Troponin consists of three regulatory proteins: T, which connects the troponin complex and tropomyosin (another cardiac muscle regulatory protein); I, which prevents muscle contraction in the absence of calcium; C, which binds calcium. Cardiac Troponin I (MW 22.5 kDa) and the two skeletal muscle isoforms of Troponin I have considerable amino acid sequence homology, but cTnI contains an additional N-terminal sequence and is highly specific for myocardium.

Clinical studies have demonstrated the release of cTnI into the blood stream within hours following acute myocardial infarction (AMI) or ischemic damage. Elevated levels of cTnI are detectable in blood within 4 to 6 hours after the onset of chest pain, reaching peak concentrations in approximately 8 to 28 hours, and remain elevated for 3 to 10 days following AMI. Due to the high myocardial specificity and the long duration of elevation, cTnI has become an important marker in the diagnosis and evaluation of patients suspected of having an AMI.

The current guideline of The Joint European Society of Cardiology/ American College of Cardiology Committee support the use of cTnI as a preferred marker of myocardial injury. Several major studies have shown that cTnI is also a predictor of cardiac risk in patients with unstable angina. The American College of Cardiology and the American Heart Association's current guidelines recommend using troponin results when making treatment decisions regarding unstable angina and non-ST segment elevation MI (NSTEMI).

PRINCIPLE

The test uses an anti-human cTnI monoclonal antibody conjugated with fluorescence latex and another anti-human cTnI monoclonal antibody coated on the test line. After the sample has been applied to the test strip, the fluorescence latex-labelled anti-human cTnI monoclonal antibody binds with the cTnI in sample and forms a marked antigen-antibody complex. This complex moves to the test card detection zone by capillary action. Then marked antigen-antibody complex is captured on the test line by the anti-human cTnI monoclonal antibody. The fluorescence intensity of the test line increases in proportion to the amount of cTnI in sample.

Then insert test card into Getein1100 Immunofluorescence Quantitative Analyzer/Getein1600 Immunofluorescence Quantitative Analyzer (hereinafter referred to as Getein1100 and Getein1600), the concentration of cTnI in sample will be measured and displayed on the screen. The value will be stored in Getein1100/Getein1600 and available for downloading. The result can be easily transmitted to the laboratory or hospital information system.

CONTENTS

1. A kit for Getein1100 contains:
   Getein cTnI test card in a sealed pouch with desiccant 25
   Disposable pipet 25
   Whole blood buffer 1
   SD card 1
   User manual 1
2. A kit for Getein1600 contains:
   Sealed cartridge with 24/48 Getein cTnI test cards 2
   User manual 1
   Package specifications:
   2×24 tests/kit, 2×48 tests/kit
   Materials required for Getein1600:
   Sample diluent 1
   Box with pipette tips 1
   Mixing plate 1
3. Sample diluent/Whole blood buffer composition:
   Phosphate buffered saline, proteins, detergent, preservative, stabilizer.
4. A test card consists of:
   A plastic shell and a reagent strip which is composed of a sample pad, nitrocellulose membrane (one end of the membrane is coated with a fluorescence latex-labelled anti-human cTnI monoclonal antibody, the test line is coated with another anti-human cTnI monoclonal antibody, and the control line is coated with rabbit anti-mouse IgG antibody), absorbent paper and liner.

Note: Do not mix or interchange different batches of kits.

APPLICABLE DEVICE

Getein1100 Immunofluorescence Quantitative Analyzer
Getein1600 Immunofluorescence Quantitative Analyzer

STORAGE AND STABILITY

Store the test card at 4~30℃ with a valid period of 24 months. Use the test card for Getein1100 within 1 hour once the foil pouch is opened.

For test card of Getein1600: if the cartridge is opened, it could be stable within 24 hours once exposed to air. If the test cards can't be used up at a time, please put the cartridge back to the foil pouch and reseal along the entire edge of zip-seal. The remaining test cards should be used up within 7 days.

Store the sample diluent/whole blood buffer at 0~30℃ with a valid period of 24 months.

Store the sample diluent/whole blood buffer at 2~8℃ for better results.

PRECAUTIONS

1. For *in vitro* diagnostic use only.
2. For professional use only.
3. Do not use the kit beyond the expiration date.
4. Do not use the test card if the foil pouch or the cartridge is damaged.
5. Do not open pouches or the cartridge until ready to perform the test.
6. Do not reuse the test card.
7. Do not reuse the pipet.
8. Handle all specimens as potentially infectious. Proper handling and disposal methods should be followed in accordance with local regulations.
9. Carefully read and follow user manual to ensure proper test performance.

SPECIMEN COLLECTION AND PREPARATION

1. This test can be used for ***serum, plasma and whole blood samples. Heparin and sodium citrate*** should be used as the anticoagulant for plasma and whole blood. Samples should be free of hemolysis.

2. Suggest using serum or plasma for better results.
3. Serum or plasma can be used directly. For whole blood sample, one drop of whole blood buffer must be added before testing.
4. If testing will be delayed, serum and plasma samples may be stored up to 7 days at 2~8℃ or stored at -20℃ for 6 months before testing (whole blood sample may be stored up to 3 days at 2~8℃).
5. Refrigerated or frozen sample should reach room temperature and be homogeneous before testing. Avoid multiple freeze-thaw cycles.
6. Do not use heat-inactivated samples.
7. SAMPLE VOLUME *(for Getein1100): 100 µl*.

TEST PROCEDURE

1. Collect specimens according to user manual.
2. Test card, sample and reagent should be brought to room temperature before testing.

For Getein1100:

3. Confirm SD card lot No. in accordance with test kit lot No.. Perform “SD Card Calib” calibration when necessary (Details refer to 8.5.2 of Getein1100 User Manual).
4. On the main interface of Getein1100, press "ENT" button to enter testing interface.
5. Remove the test card from the sealed pouch immediately before use. Label the test card with patient or control identification.
6. Put the test card on a clean table, horizontally placed.
7. Using sample transfer pipette, deliver *100 µl* of sample (or 3~4 drops of sample when using disposable pipet) into the sample port on the test card (for whole blood sample, one drop of whole blood buffer must be added after loading 100 µl sample on the test card).
8. *Reaction time: 10 minutes.* Insert the test card into Getein1100 and press "ENT" button after reaction time is elapsed. The result will be shown on the screen and printed automatically.

For Getein1600:

9. Each cartridge for Getein1600 contains a specific RFID card which can calibrate automatically.
10. Place samples in the designed area of the sample holder, insert the holder and select the right test item, Getein1600 will do the testing and print the result automatically.

Notes:

1. It is required to perform “SD Card Calib” calibration when using a new batch of kits.
2. It is suggested to calibrate once for one batch of kits for Getein1100.
3. Make sure the test card and the sample insertion is correct and complete.

TEST RESULTS

Getein1100/Getein1600 can scan the test card automatically and display the result on the screen. For additional information, please refer to the user manual of Getein1100/Getein1600.

EXPECTED VALUE

The expected normal value for Troponin I was determined by testing samples from 500 apparently healthy individuals. The 99th percentile of the concentration for cTnI is 0.1 ng/ml. (The probability that value of a normal person below 0.1 ng/ml is 99%.)
It is recommended that each laboratory establish its own expected values for the population it serves.

PERFORMANCE CHARACTERISTICS

Measuring Range	0.1~50 ng/ml
Lower Detection Limit	≤ 0.1 ng/ml
Within-Run Precision	≤10%
Between-Run Precision	≤15%

Method Comparison:

The assay was compared with SIEMENS IMMULITE 2000 and its matching cTnI test kits with 200 serum samples (60 positive samples and 140 negative samples). The correlation coefficient (r) for cTnI is 0.952.

LIMITATIONS

1. As with all diagnostic tests, a definitive clinical diagnosis should not be made based on the result of a single test. The test results should be interpreted considering all other test results and clinical information such as clinical signs and symptoms.
2. Samples containing interferents may influence the results. The table below listed the maximum allowance of these potential interferents.

Interferent	Hemoglobin	Triglyceride	Bilirubin
Concentration (Max)	5 g/L	10 g/L	0.2 g/L

REFERENCES

1. Mauro Pantaghini. Undefined International Federation of Clinical Chemistry and Laboratory Medicine (IFCC). Scientific Division Committee on Standardization of Markers of Cardiac Damage. Clin Chem Lab Med, 1998, 36:887~893.
2. Antman EM, Anbe DT, Armstrong PW, et al. ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Revise the 1999 Guidelines for the Manage 2004).
3. EN ISO 18113-1:2009 *In vitro* diagnostic medical devices - Information supplied by the manufacturer (labelling) - Part 1: Terms, definitions and general requirements.
4. EN ISO 18113-2:2009 *In vitro* diagnostic medical devices - Information supplied by the manufacturer (labelling) - Part 2: *In vitro* diagnostic reagents for professional use (ISO 18113-2:2009).

DESCRIPTION OF SYMBOLS USED

The following graphical symbols used in or found on Cardiac Troponin I Fast Test Kit (Immunofluorescence Assay) are the most common ones appearing on medical devices and their packaging. They are explained in more details in the European Standard EN 980:2008 and International Standard ISO 15223-1:2007.

Key to symbols used			
	Manufacturer		Expiration date
	Do not reuse		Date of manufacture
	Consult instructions for use	LOT	Batch code
	Temperature limitation	IVD	*In vitro* diagnostic medical device
Σ	Sufficient for	EC REP	Authorized representative in the European Community
CE	CE mark		Do not use if package is damaged

Thank you for purchasing Cardiac Troponin I Fast Test Kit (Immunofluorescence Assay). Please read this user manual carefully before operating to ensure proper use.

Version: WIF02-S-02

Getein Biotech, Inc.
Add: No.9 Bofu Road, Luhe District, Nanjing, 211505, China
Tel: +86-25-68568508
Fax: +86-25-68568500
E-mail: tech@getein.com.cn
overseas@getein.com.cn
Website: www.bio-GP.com.cn

CE IVD

CysC
Fast Test Kit
(Immunofluorescence Assay)

User Manual

Getein1100: Cat.# IF1008
Getein1600: Cat.# IF2008

INTENDED USE

CysC Fast Test Kit (Immunofluorescence Assay) is intended for *in vitro* quantitative determination of Cystatin C (CysC) in serum, plasma or whole blood. The test result is used as an aid in the assessment and evaluation of index of glomerular filtration rate, and has important application value in renal function, kidney damage and renal transplantation.

SUMMARY

Cystatin C (CysC) is mainly used as a biomarker of kidney function. Cystatin C has a low molecular weight (approximately 13.3 kilodaltons), and it is removed from the bloodstream by glomerular filtration in the kidneys. If kidney function and glomerular filtration rate decline, the blood levels of cystatin C rise. Serum levels of cystatin C are a more precise test of kidney function (as represented by the glomerular filtration rate, GFR) than serum creatinine levels.
This finding is based mainly on cross-sectional studies (on a single point in time). Longitudinal studies (that follow cystatin C over time) are scarcer; some studies show promising results. Cystatin C levels are less dependent on age, sex, race and muscle mass compared to creatinine. Cystatin C measurement alone has not been shown to be superior to formula-adjusted estimations of kidney function. As opposed to previous claims, Cystatin C has been found to be influenced by body composition. It has been suggested that cystatin C might predict the risk of developing chronic kidney disease, thereby signaling a state of 'preclinical' kidney dysfunction.

PRINCIPLE

The test uses an anti-human CysC monoclonal antibody conjugated with fluorescence latex and another anti-human CysC monoclonal antibody coated on the test line. After the sample has been applied to the test strip, the fluorescence latex-labelled anti-human CysC monoclonal antibody binds with the CysC in sample and forms a marked antigen-antibody complex. This complex moves to the test card detection zone by capillary action, then be captured on the test line by another anti-human CysC monoclonal antibody. The fluorescence intensity of the test line increases in proportion to the amount of CysC in sample.
Then insert test card into Getein1100 Immunofluorescence Quantitative Analyzer/Getein1600 Immunofluorescence Quantitative Analyzer (hereinafter referred to as Getein1100 and Getein1600), the concentration of CysC in sample will be measured and displayed on the screen. The value will be stored in Getein1100/Getein1600 and available for downloading. The result can be easily transmitted to the laboratory or hospital information system.

CONTENTS

1. A kit for Getein1100 contains:
   Getein CysC test card in a sealed pouch with desiccant 25
   Disposable pipet 25
   Sample diluent 25
   SD card 1
   User manual 1
2. A kit for Getein1600 contains:
   Sealed cartridge with 24/48 Getein CysC test cards 2
   User manual 1
   Package specifications:
   2×24 tests/kit, 2×48 tests/kit
   Materials required for Getein1600:
   Sample diluent 1
   Box with pipette tips 1
   Coated wells 1
3. Sample diluent composition:
   Phosphate buffered saline, proteins, detergent, preservative, stabilizer.
4. A test card consists of:
   A plastic shell and a reagent strip which is composed of a sample pad, nitrocellulose membrane (one end of the membrane is coated with a fluorescence-labelled anti-human CysC monoclonal antibody, the test line is coated with another anti-human CysC monoclonal antibody and the control line is coated with rabbit anti-mouse IgG antibody), absorbent paper and liner.

Note: Do not mix or interchange different batches of kits.

APPLICABLE DEVICE

Getein1100 Immunofluorescence Quantitative Analyzer
Getein1600 Immunofluorescence Quantitative Analyzer

STORAGE AND STABILITY

Store the test card at 4~30℃ with a valid period of 24 months. Use the test card for Getein1100 within 1 hour once the foil pouch is opened.
For test card of Getein1600: if the cartridge is opened, it could be stable within 24 hours once exposed to air. If the test cards can't be used up at a time, please put the cartridge back to the foil pouch and reseal along the entire edge of zip-seal. The remaining test cards should be used up within 7 days.
Store the sample diluent/whole blood buffer at 0~30℃ with a valid period of 24 months.
Store the sample diluent/whole blood buffer at 2~8℃ for better results.

PRECAUTIONS

1. For *in vitro* diagnostic use only.
2. For professional use only.
3. Do not use the kit beyond the expiration date.
4. Do not use the test card if the foil pouch or the cartridge is damaged.
5. Do not open pouches or the cartridge until ready to perform the test.
6. Do not reuse the test card.
7. Do not reuse the pipet.
8. Handle all specimens as potentially infectious. Proper handling and disposal methods should be followed in accordance with local regulations.
9. Carefully read and follow user manual to ensure proper test performance.

SPECIMEN COLLECTION AND PREPARATION

1. This test can be used for ***serum, plasma and whole blood samples. Sodium citrate*** should be used as the anticoagulant for plasma and whole blood. Samples should be free of hemolysis.
2. Suggest using serum or plasma for better results.
3. If testing will be delayed, serum and plasma samples may be stored up to 7 days at 2~8℃ or stored at -20℃ for 6

months before testing (whole blood sample may be stored up to 3 days at 2~8℃).
4. Refrigerated or frozen sample should reach room temperature and be homogeneous before testing. Avoid multiple freeze-thaw cycles.
5. Do not use heat-inactivated samples.
6. SAMPLE VOLUME *(for Getein1100): 10 µl*.

TEST PROCEDURE

1. Collect specimens according to user manual.
2. Test card, sample and reagent should be brought to room temperature before testing.

For Getein1100:

3. Confirm SD card lot No. in accordance with test kit lot No.. Perform “SD Card Calib” calibration when necessary (Details refer to 8.5.2 of Getein1100 User Manual).
4. On the main interface of Getein1100, press "ENT" button to enter testing interface.
5. Remove the test card from the sealed pouch immediately before use. Label the test card with patient or control identification.
6. Put the test card on a clean table, horizontally placed.
7. Using sample transfer pipette, deliver *10 µl* of sample into one tube of sample diluent, mix gently and thoroughly. Then drop *100 µl* of sample mixture (or 3~4 drops of sample mixture when using disposable pipet) into the sample port on the test card.
8. *Reaction time: 3 minutes.* Insert the test card into Getein1100 and press "ENT" button after reaction time is elapsed. The result will be shown on the screen and printed automatically.

For Getein1600:

9. Each cartridge for Getein1600 contains a specific RFID card which can calibrate automatically.
10. Place samples in the designed area of the sample holder, insert the holder and select the right test item, Getein1600 will do the testing and print the result automatically.

Notes:

1. It is required to perform “SD Card Calib” calibration when using a new batch of kits for Getein1100.
2. It is suggested to calibrate once for one batch of kits for Getein1100.
3. Make sure the test card insertion is correct and complete.

TEST RESULTS

Getein1100/Getein1600 can scan the test card automatically and display the result on the screen. For additional information, please refer to the user manual of Getein1100/Getein1600.

EXPECTED VALUE

The expected normal value for CysC was determined by testing samples from 233 apparently healthy individuals. The reference range of CysC is 0.51 mg/L~1.09 mg/L calculated by using normal distribution methods.
It is recommended that each laboratory establish its own expected values for the population it serves.

PERFORMANCE CHARACTERISTICS

Measuring Range	0.5~10.0 mg/L
Lower Detection Limit	≤0.5 mg/L
Within-Run Precision	≤10%
Between-Run Precision	≤15%

Method Comparison:

The assay was compared with HITACHI 7170A analyzer and its matching MAKER CysC test kits with 204 serum samples (30 positive samples and 174 negative samples). The correlation coefficient (r) is 0.985.

LIMITATIONS

1. As with all diagnostic tests, a definitive clinical diagnosis should not be made based on the result of a single test. The test results should be interpreted considering all other test results and clinical information such as clinical signs and symptoms.
2. Samples containing interferents may influence the results. The table below listed the maximum allowance of these potential interferents.

Interferent	Hemoglobin	Triglyceride	Bilirubin
Concentration (Max)	10 g/L	10 g/L	0.2 g/L

REFERENCES

1. Bjurman C, Snygg-Martin U, Olaison L, et al. Cystatin C in a composite risk score for mortality in patients with infective endocarditis: a cohort study. BMJ Open. 2012, Jul 12, 2(4).
2. Chae HW, Shin JI, Kwon AR, et al. Spot urine albumin to creatinine ratio and serum cystatin C are effective for detection of diabetic nephropathy in childhood diabetic patients. J Korean Med Sci. 2012, 27(7):784-787.
3. Odutayo A, Cherney D. Cystatin C and acute changes in glomerular filtration rate. Clin Nephrol. 2012, 78(1):64-75.
4. EN ISO 18113-1:2009 *In vitro* diagnostic medical devices - Information supplied by the manufacturer (labelling) - Part 1: Terms, definitions and general requirements.
5. EN ISO 18113-2:2009 *In vitro* diagnostic medical devices - Information supplied by the manufacturer (labelling) - Part 2: *In vitro* diagnostic reagents for professional use (ISO 18113-2: 2009).

DESCRIPTION OF SYMBOLS USED

The following graphical symbols used in or found on CysC Fast Test Kit (Immunofluorescence Assay) are the most common ones appearing on medical devices and their packaging. They are explained in more details in the European Standard EN 980:2008 and International Standard ISO 15223-1:2007.

Key to symbols used			
	Manufacturer		Expiration date
	Do not reuse		Date of manufacture
	Consult instructions for use	LOT	Batch code
	Temperature limitation	IVD	*In vitro* diagnostic medical device
	Sufficient for	EC REP	Authorized representative in the European Community
CE	CE mark		Do not use if package is damaged

Thank you for purchasing CysC Fast Test Kit (Immunofluorescence Assay). Please read this user manual carefully before operating to ensure proper use.

Version: WIF13-S-02

Getein Biotech, Inc.
Add: No.9 Bofu Road, Luhe District, Nanjing, 211505, China
Tel: +86-25-68568508
Fax: +86-25-68568500
E-mail: tech@getein.com.cn
overseas@getein.com.cn
Website: www.bio-GP.com.cn

CE IVD

D-Dimer

Fast Test Kit

(Immunofluorescence Assay)

User Manual

Getein1100: Cat.# IF1006
Getein1600: Cat.# IF2006

INTENDED USE

D-Dimer Fast Test Kit (Immunofluorescence Assay) is intended for *in vitro* quantitative determination of D-Dimer in plasma or whole blood. The test is used as an aid in the assessment and evaluation of patients suspected of deep-vein thrombosis or pulmonary embolism.

SUMMARY

Deep-vein thrombosis is a common condition, with a lifetime cumulative incidence of 2 to 5 percent. Untreated deep-vein thrombosis can result in pulmonary embolism, a potentially fatal outcome. Anticoagulant therapy reduces both morbidity and mortality from venous thromboembolism, and early diagnosis is therefore important. Accurate diagnosis of deep-vein thrombosis minimizes the risk of thromboembolic complications and averts the exposure of patients without thrombosis to the risks of anticoagulant therapy.

D-Dimer is a marker of endogenous fibrinolysis and should therefore be detectable in patients with deep-vein thrombosis. In recent years, an increasing number of studies have shown the D-Dimer assay has a high negative predictive value and D-Dimer is a sensitive but nonspecific marker of deep-vein thrombosis. Negative D-Dimer can exclude deep-vein thrombosis and pulmonary embolism.

PRINCIPLE

The test uses an anti-human D-Dimer monoclonal antibody conjugated with fluorescence latex and another anti-human D-Dimer monoclonal antibody coated on the test line. After the sample has been applied to the test strip, the fluorescence latex-labelled anti-human D-Dimer monoclonal antibody binds with the D-Dimer in sample and forms a marked antigen-antibody complex. This complex moves to the test card detection zone by capillary action. Then marked antigen-antibody complex is captured on the test line by another anti-human D-Dimer monoclonal antibody. The fluorescence intensity of the test line increases in proportion to the amount of D-Dimer in sample.

Then insert test card into Getein1100 Immunofluorescence Quantitative Analyzer/Getein1600 Immunofluorescence Quantitative Analyzer (hereinafter referred to as Getein1100 and Getein1600), the concentration of D-Dimer in sample will be measured and displayed on the screen. The value will be stored in Getein1100/Getein1600 and available for downloading. The result can be easily transmitted to the laboratory or hospital information system.

CONTENTS

1. A kit for Getein1100 contains:
   Getein D-Dimer test card in a sealed pouch with desiccant 25
   Disposable pipet 25
   Sample diluent 25
   SD card 1
   User manual 1
2. A kit for Getein1600 contains:
   Sealed cartridge with 24/48 Getein D-Dimer test cards 2
   User manual 1
   Package specifications:
   2×24 tests/kit, 2×48 tests/kit
   Materials required for Getein1600:
   Sample diluent 1
   Box with pipette tips 1
   Mixing plate 1
3. Sample diluent composition:
   Phosphate buffered saline, proteins, detergent, preservative, stabilizer.
4. A test card consists of:
   A plastic shell and a reagent strip which is composed of a sample pad, nitrocellulose membrane (one end of the membrane is coated with a fluorescence latex-labelled anti-human D-Dimer monoclonal antibody, the test line is coated with another anti-human D-Dimer monoclonal antibody and the control line is coated with rabbit anti-mouse IgG antibody), absorbent paper and liner.

Note: Do not mix or interchange different batches of kits.

APPLICABLE DEVICE

Getein1100 Immunofluorescence Quantitative Analyzer
Getein1600 Immunofluorescence Quantitative Analyzer

STORAGE AND STABILITY

Store the test card at 4~30℃ with a valid period of 24 months. Use the test card for Getein1100 within 1 hour once the foil pouch is opened.

For test card of Getein1600: if the cartridge is opened, it could be stable within 24 hours once exposed to air. If the test cards can't be used up at a time, please put the cartridge back to the foil pouch and reseal along the entire edge of zip-seal. The remaining test cards should be used up within 7 days.

Store the sample diluent/whole blood buffer at 0~30℃ with a valid period of 24 months.

Store the sample diluent/whole blood buffer at 2~8℃ for better results.

PRECAUTIONS

1. For *in vitro* diagnostic use only.
2. For professional use only.
3. Do not use the kit beyond the expiration date.
4. Do not use the test card if the foil pouch or the cartridge is damaged.
5. Do not open pouches or the cartridge until ready to perform the test.
6. Do not reuse the test card.
7. Do not reuse the pipet.
8. Handle all specimens as potentially infectious. Proper handling and disposal methods should be followed in accordance with local regulations.
9. Carefully read and follow user manual to ensure proper test performance.

SPECIMEN COLLECTION AND PREPARATION

1. This test can be used for ***plasma and whole blood samples.*** ***Sodium citrate*** can be used as the anticoagulant for plasma and whole blood. Samples should be free of hemolysis.
2. Suggest using plasma for better results.
3. If testing will be delayed, plasma sample may be stored up to 3 days at 2~8℃ or stored at -20℃ for 1 month before testing (whole blood sample may be stored up to 3 days at 2~8℃).
4. Refrigerated or frozen sample should reach room temperature

and be homogeneous before testing. Avoid multiple freeze-thaw cycles.
5. Do not use heat-inactivated samples.
6. SAMPLE VOLUME *(for Getein1100): 100 µl*.

TEST PROCEDURE

1. Collect specimens according to user manual.
2. Test card, sample and reagent should be brought to room temperature before testing.

For Getein1100:

3. Confirm SD card lot No. in accordance with test kit lot No.. Perform “SD Card Calib” calibration when necessary (Details refer to 8.5.2 of Getein1100 User Manual).
4. On the main interface of Getein1100, press "ENT" button to enter testing interface.
5. Remove the test card from the sealed pouch immediately before use. Label the test card with patient or control identification.
6. Put the test card on a clean table, horizontally placed.
7. Using sample transfer pipette, deliver *100 µl* of sample into one tube of sample diluent, mix gently and thoroughly. Then drop 100 µl of sample mixture (or 3~4 drops of sample when using disposable pipet) into the sample port on the test card.
8. *Reaction time: 10 minutes.* Insert the test card into Getein1100 and press "ENT" button after reaction time is elapsed. The result will be shown on the screen and printed automatically.

For Getein1600:

9. Each cartridge for Getein1600 contains a specific RFID card which can calibrate automatically.
10. Place samples in the designed area of the sample holder, insert the holder and select the right test item, Getein1600 will do the testing and print the result automatically.

Notes:

1. It is required to perform “SD Card Calib” calibration when using a new batch of kits.
2. It is suggested to calibrate once for one batch of kits for Getein1100.
3. Make sure the test card and the sample insertion is correct and complete.

TEST RESULTS

Getein1100/Getein1600 can scan the test card automatically and display the result on the screen. For additional information, please refer to the user manual of Getein1100/Getein1600.

EXPECTED VALUE

The expected normal value for D-Dimer was determined by testing samples from 500 apparently healthy individuals. The 95th percentile of the concentration for D-Dimer is 0.5 mg/L. (The probability that value of a normal person below 0.5 mg/L is 95%.)

It is recommended that each laboratory establish its own expected values for the population it serves.

PERFORMANCE CHARACTERISTICS

Measuring Range	0.1~10.0 mg/L
Lower Detection Limit	≤0.1 mg/L
Within-Run Precision	≤10%
Between-Run Precision	≤15%

Method Comparison:

The assay was compared with SIEMENS CA-7000 and its matching D-Dimer test kits with 200 plasma samples (60 positive samples and 140 negative samples). The correlation coefficient (r) for D-Dimer is 0.978.

LIMITATIONS

1. As with all diagnostic tests, a definitive clinical diagnosis should not be made based on the result of a single test. The test results should be interpreted considering all other test results and clinical information such as clinical signs and symptoms.
2. Samples containing interferents such as rheumatoid factor, human anti-mouse antibody and heterophile antibody may influence the results. In this case, results of this test should be used in conjunction with clinical findings and other tests. The table below listed the maximum allowance of these potential interferents.

Interferent	Hemoglobin	Triglyceride	Bilirubin
Concentration (Max)	5 g/L	25 g/L	0.1 g/L

REFERENCES

1. Sarig G, Klil-Drori AJ, Chap-Marshak D, Brenner B, Drugan A. Activation of coagulation in amniotic fluid during normal human pregnancy.Thromb Res. 2011 Apr 18.
2. Roldán V, Marín F, Muiña B, Torregrosa JM, Hernández-Romero D, Valdés M, Vicente V, Lip GY. Plasma von Willebrand Factor Levels Are an Independent Risk Factor for Adverse Events Including Mortality and Major Bleeding in Anticoagulated Atrial Fibrillation Patients. J Am Coll Cardiol. 2011 Apr 11.
3. Sakamoto K, Yamamoto Y, Okamatsu H, Okabe M. D-dimer is helpful for differentiating acute aortic dissection and acute pulmonary embolism from acute myocardial infarction. Hellenic J Cardiol. 2011 Mar-Apr; 52(2):123-127.
4. EN ISO 18113-1:2009 *In vitro* diagnostic medical devices - Information supplied by the manufacturer (labelling) - Part 1: Terms, definitions and general requirements.
5. EN ISO 18113-2:2009 *In vitro* diagnostic medical devices - Information supplied by the manufacturer (labelling) - Part 2: *In vitro* diagnostic reagents for professional use (ISO 18113-2:2009).

DESCRIPTION OF SYMBOLS USED

The following graphical symbols used in or found on D-Dimer Fast Test Kit (Immunofluorescence Assay) are the most common ones appearing on medical devices and their packaging. They are explained in more details in the European Standard EN 980:2008 and International Standard ISO 15223-1:2007.

Key to symbols used			
	Manufacturer		Expiration date
	Do not reuse		Date of manufacture
	Consult instructions for use	LOT	Batch code
	Temperature limitation	IVD	*In vitro* diagnostic medical device
	Sufficient for	EC REP	Authorized representative in the European Community
CE	CE mark		Do not use if package is damaged

Thank you for purchasing D-Dimer Fast Test Kit (Immunofluorescence Assay). Please read this user manual carefully before operating to ensure proper use.

Version: WIF05-S-02

Getein Biotech, Inc.
Add: No.9 Bofu Road, Luhe District, Nanjing, 211505, China
Tel: +86-25-68568508
Fax: +86-25-68568500
E-mail: tech@getein.com.cn
overseas@getein.com.cn
Website: www.bio-GP.com.cn

CE IVD

PCT

Fast Test Kit

(Immunofluorescence Assay)

User Manual

Getein1100: Cat.# IF1007
Getein1600: Cat.# IF2007

INTENDED USE

PCT Fast Test Kit (Immunofluorescence Assay) is intended for *in vitro* quantitative determination of Procalcitonin (PCT) in serum, plasma or whole blood. The test is used as an aid in the assessment and evaluation of patients suspected of bacterial infection, trauma or shock.

SUMMARY

PCT is a peptide precursor of the hormone calcitonin, the latter being involved with calcium homeostasis. It is composed of 116 amino acids and is produced by parafollicular cells (C cells) of the thyroid and by the neuroendocrine cells of the lung and the intestine.
Measurement of PCT can be used as a marker of severe sepsis and generally grades well with the degree of sepsis, although levels of PCT in the blood are very low. PCT has the greatest sensitivity and specificity for differentiating patients with systemic inflammatory response syndrome (SIRS) from those with sepsis.
PCT levels may be useful to distinguish bacterial infections from nonbacterial infections. It has shown that PCT may help guide therapy and reduce antibiotic use, which can help save on cost of antibiotic prescriptions and drug resistance.

PRINCIPLE

The test uses an anti-human PCT monoclonal antibody conjugated with fluorescence latex. For PCT product, test line 1 was coated with anti-human PCT polyclonal antibody and test line 2 was coated with another anti-human PCT monoclonal antibody. After the sample has been applied to the test strip, the fluorescence latex-labelled anti-human PCT monoclonal antibody binds with the PCT in sample and forms a marked antigen-antibody complex. This complex moves to the test card detection zone by capillary action. Then marked antigen antibody complex is captured on the test line by the other anti-human PCT monoclonal antibody or the polyclonal antibody. The fluorescence intensity of the test line increases in proportion to the amount of PCT in sample.
Then insert test card into Getein1100 Immunofluorescence Quantitative Analyzer/Getein1600 Immunofluorescence Quantitative Analyzer (hereinafter referred to as Getein1100 and Getein1600), the concentration of PCT in sample will be measured and displayed on the screen. The value will be stored in Getein1100/Getein1600 and available for downloading. The result can be easily transmitted to the laboratory or hospital information system.

CONTENTS

1. A kit for Getein1100 contains:
   Getein PCT test card in a sealed pouch with desiccant 25
   Disposable pipet 25
   Whole blood buffer 1
   SD card 1
   User manual 1
2. A kit for Getein1600 contains:
   Sealed cartridge with 24/48 Getein PCT test cards 2
   User manual 1
   Package specifications:
   2×24 tests/kit, 2×48 tests/kit
   Materials required for Getein1600:
   Sample diluent 1
   Box with pipette tips 1
   Mixing plate 1
3. Sample diluent/Whole blood buffer composition:
   Phosphate buffered saline, proteins, detergent, preservative, stabilizer.
4. A test card consists of:
   A plastic shell and a reagent strip which is composed of a sample pad, fluorescence latex pad, nitrocellulose membrane (one end of the membrane is coated with a fluorescence latex-labelled anti-human PCT monoclonal antibody, the test line are coated with another anti-human PCT monoclonal antibody and polyclonal antibody, and the control line is coated with rabbit anti-mouse IgG antibody), absorbent paper and liner.

Note: Do not mix or interchange different batches of kits.

APPLICABLE DEVICE

Getein1100 Immunofluorescence Quantitative Analyzer
Getein1600 Immunofluorescence Quantitative Analyzer

STORAGE AND STABILITY

Store the test card at 4~30℃ with a valid period of 24 months. Use the test card for Getein1100 within 1 hour once the foil pouch is opened.
For test card of Getein1600: if the cartridge is opened, it could be stable within 24 hours once exposed to air. If the test cards can't be used up at a time, please put the cartridge back to the foil pouch and reseal along the entire edge of zip-seal. The remaining test cards should be used up within 7 days.
Store the sample diluent/whole blood buffer at 0~30℃ with a valid period of 24 months.
Store the sample diluent/whole blood buffer at 2~8℃ for better results.

PRECAUTIONS

1. For *in vitro* diagnostic use only.
2. For professional use only.
3. Do not use the kit beyond the expiration date.
4. Do not use the test card if the foil pouch or the cartridge is damaged.
5. Do not open pouches or the cartridge until ready to perform the test.
6. Do not reuse the test card.
7. Do not reuse the pipet.
8. Handle all specimens as potentially infectious. Proper handling and disposal methods should be followed in accordance with local regulations.
9. Carefully read and follow the manual to ensure proper test performance.

SPECIMEN COLLECTION AND PREPARATION

1. This test can be used for ***serum, plasma and whole blood samples. Heparin and sodium citrate*** should be used as the anticoagulant for plasma and whole blood. Samples should be free of hemolysis.
2. Suggest using serum or plasma for better results.
3. Serum or plasma can be used directly. For whole blood sample, one drop of whole blood buffer must be added before testing.
4. If testing will be delayed, serum and plasma samples may be stored up to 7 days at 2~8℃ or stored at -20℃ for 6 months before testing (whole blood sample may be stored up to 3 days at 2~8℃).
5. Refrigerated or frozen sample should reach room temperature and be homogeneous before testing. Avoid multiple freeze-thaw cycles.
6. Do not use heat-inactivated samples.
7. SAMPLE VOLUME ***(for Getein1100): 100 µl***.

TEST PROCEDURE

1. Collect specimens according to user manual.
2. Test card, sample and reagent should be brought to room temperature before testing.

For Getein1100:

3. Confirm SD card lot No. in accordance with test kit lot No.. Perform “SD Card Calib” calibration when necessary (Details refer to 8.5.2 of Getein1100 User Manual).
4. On the main interface of Getein1100, press "ENT" button to enter testing interface.
5. Remove the test card from the sealed pouch immediately before use. Label the test card with patient or control identification.
6. Put the test card on a clean table, horizontally placed.
7. Using sample transfer pipette, deliver ***100 µl*** of sample (or 3~4 drops of sample when using disposable pipet) into the sample port on the test card (for whole blood sample, one drop of whole blood buffer must be added after loading 100 µl sample on the test card).
8. ***Reaction time: 15 minutes.*** Insert the test card into Getein1100 and press "ENT" button after reaction time is elapsed. The result will be shown on the screen and printed automatically.

For Getein1600:

9. Each cartridge for Getein1600 contains a specific RFID card which can calibrate automatically.
10. Place samples in the designed area of the sample holder, insert the holder and select the right test item, Getein1600 will do the testing and print the result automatically.

Notes:

1. It is required to perform “SD Card Calib” calibration when using a new batch of kits.
2. It is suggested to calibrate once for one batch of kits for Getein1100.
3. Make sure the test card and the sample insertion is correct and complete.

TEST RESULTS

Getein1100/Getein1600 can scan the test card automatically and display the result on the screen. For additional information, please refer to the user manual of Getein1100/Getein1600.

EXPECTED VALUE

The expected normal value for PCT was determined by testing samples from 500 apparently healthy individuals. The 99th percentile of the concentration for PCT is 0.1 ng/ml. (The probability that value of a normal person below 0.1 ng/ml is 99%.) The table below comes from the research of ACCP/SCCM (American College of Chest Physicians/Society of Critical Care Medicine), showing the PCT value and its clinical meaning [4]:

PCT concentration	Clinical significance
< 0.5 ng/ml	Local bacterial infection is possible, systemic infection (sepsis) is not likely.
≥ 0.5 and < 2.0 ng/ml	Systemic infection (sepsis) is possible, a moderate risk of severe sepsis and/or septic shock.
≥ 2.0 ng/ml	Systemic infection (sepsis) is likely, a high risk of severe sepsis and/or septic shock.

It is recommended that each laboratory establish its own expected values for the population it serves.

PERFORMANCE CHARACTERISTICS

Measuring Range	0.1~50.0 ng/ml
Lower Detection Limit	≤0.1 ng/ml
Within-Run Precision	≤10%
Between-Run Precision	≤15%

Method Comparison:

The assay was compared with Roche MODULAR ANALYTICS E170 automatic immunoassay system and its matching PCT test kits with 200 serum samples (68 positive samples and 132 negative samples). The correlation coefficient (r) for PCT is 0.983.

LIMITATIONS

1. As with all diagnostic tests, a definitive clinical diagnosis should not be made based on the result of a single test. The test results should be interpreted considering all other test results and clinical information such as clinical signs and symptoms.
2. Samples containing interferent may influences the results. The table below listed the maximum allowance of these potential interferents.

Interferent	Hemoglobin	Triglyceride	Bilirubin
Concentration (Max)	5 g/L	10 g/L	0.2 g/L

REFERENCES

1. Balcl C, Sungurtekin H, Gürses E, Sungurtekin U, Kaptanoglu B. Usefulness of procalcitonin for diagnosis of sepsis in the intensive care unit, Crit Care. 2003 February 7 (1):85~90.
2. Schuetz P, Christ-Crain M, Thomann R, et al. Effect of procalcitonin-based guidelines vs standard guidelines on antibiotic use in lower respiratory tract infections: the ProHOSP randomized controlled trial. JAMA. Sep 9 2009; 302(10):1059-66.
3. Briel M, Schuetz P, Mueller B, et al. Procalcitonin-guided antibiotic use vs a standard approach for acute respiratory tract infections in primary care. Arch Intern Med. Oct 13 2008; 168(18):2000-7; discussion 2007-8.
4. Meisner M. Procalcitonin (PCT) - A New innovative infection parameter. Biochemical and clinical aspects. Thieme Stuttgart, New York 2000, ISBN: 3-13-105503-0.
5. EN ISO 18113-1:2009 *In vitro* diagnostic medical devices - Information supplied by the manufacturer (labelling) - Part 1: Terms, definitions and general requirements.
6. EN ISO 18113-2:2009 *In vitro* diagnostic medical devices - Information supplied by the manufacturer (labelling) - Part 2: *In vitro* diagnostic reagents for professional use (ISO 18113-2:2009).

DESCRIPTION OF SYMBOLS USED

The following graphical symbols used in or found on PCT Fast Test Kit (Immunofluorescence Assay) are the most common ones appearing on medical devices and their packaging. They are explained in more details in the European Standard EN 980:2008 and International Standard ISO 15223-1:2007.

Key to symbols used			
	Manufacturer		Expiration date
	Do not reuse		Date of manufacture
	Consult instructions for use	LOT	Batch code
	Temperature limitation	IVD	*In vitro* diagnostic medical device
	Sufficient for	EC REP	Authorized representative in the European Community
	CE mark		Do not use if package is damaged

Thank you for purchasing PCT Fast Test Kit (Immunofluorescence Assay). Please read this user manual carefully before operating to ensure proper use.

Version: WIF06-S-02

Getein Biotech, Inc.
Add: No.9 Bofu Road, Luhe District, Nanjing, 211505, China
Tel: +86-25-68568508
Fax: +86-25-68568500
E-mail: tech@getein.com.cn
overseas@getein.com.cn
Website: www.bio-GP.com.cn

D-Dimer Control

REF QC006

User Manual

PRODUCT NAME

D-Dimer Control

PRODUCT SPECIFICATION

Package: 3(Level)*2(Vial)*1(ml), 3(Level)*1(Vial)*1(ml)
D-Dimer Control - Level 1/2/3

INTENDED USE

This product is intended for *in vitro* diagnostic use in the quality control of D-Dimer on the Getein Platforms.

PRINCIPLE

The lyophilized D-Dimer control is prepared from dissolving stable and high quality recombinant D-Dimer antigen into calf serum. With matching equipments and reagents, it can fulfill value transfer work. As different equipments and reagents have uncertainty to some extent, different control results may appear.

CONTENTS

The kit for FIA8000/FIA8600/Getein1100 contains:

1. D-Dimer Control - Level 1
   D-Dimer Control - Level 2
   D-Dimer Control - Level 3
2. User manual: 1 piece/box
3. Target value sheet: 1 piece/box

The kit for Getein1600 contains:

1. D-Dimer Control - Level 1
   D-Dimer Control - Level 2
   D-Dimer Control - Level 3
2. User manual: 1 piece/box
3. Target value sheet: 1 piece/box
4. Quality control holder - Level 1
   Quality control holder - Level 2
   Quality control holder - Level 3

Note: Each quality control holder is labelled with barcode which contains target value and level of different items.

MATCHING EQUIPMENTS

FIA8000/8600 Quantitative Immunoassay Analyzer
Getein1100/1600 Immunofluorescence Quantitative Analyzer

STORAGE AND STABILITY

UNOPENED: The product is stable for 18 months at -20℃ and for 90 days at 2 ~ 8℃ to avoid light.
OPENED: The product is stable for 15 days at 2 ~ 8℃ if kept capped in orginal container and free from contamination. Only the required amount of product should be removed. Any residual product should NOT BE RETURNED to the original vial after using. It is recommended to be dispensed into smaller vials after dilution and stable for 30 days at -20 ~ -70℃.

MATERIALS REQUIRED BUT NOT PROVIDED

1. 1 ml pipette
2. Distilled water
3. Getein test kit
4. Getein instrument

TEST PROCEDURE

1. The product should be brought to room temperature (15 ~ 30℃) prior to use.
2. Open the vial carefully in case of the loss of content.

3. Dissolve each control material with 1 ml distilled water.
4. Close the vial and mix gently until all contents are dissolved completely. Avoid violent shaking or foam formation.
5. Keep it at room temperature for 5 ~ 10 minutes before use.

For FIA8000/FIA8600/Getein1100:

6. Treat the control in the same manner as patient specimen in the assay procedure. Follow the directions of test kit and the instrument application instruction.

For Getein1600:

7. Insert quality control holder into sample holder.
8. Insert sample holder with a constant speed and barcode facing the scanner, refer to the User Manual of Getein1600 to start QC testing.

ASSIGNED VALUES

Refer to values listed on the target value sheet.
If the result is beyond the range, it indicates the existence of some unreliable factors in the testing system. Referring to the control graph helps judge the accuracy and stability of the testing system.
The expected range of the mean is provided to aid laboratory until it has established its own mean and SD for its methods.

PERFORMANCE CHARACTERISTICS

1. Homogeneity: ≤ 15%
2. Accuracy range: Refer to the target value sheet

LIMITATIONS

1. This product can only be used on the Getein Platforms.
2. Variation exists between different equipments developed by different methods even using the same control product.
3. This product is not intended to be used as standard material.

NOTES

1. For *in vitro* diagnostic use only.
2. Do not use the product beyond the expiration date.
3. Avoid multiple freeze-thaw cycles.
4. Do not use the product if it is contaminated with bacteria.
5. Proper handling and disposal methods should be followed in accordance with local regulations.

DESCRIPTION OF SYMBOLS USED

The following graphical symbols used in or found on D-Dimer control are the most common ones appearing on medical devices and their packaging. They are explained in more details in the European Standard EN 980:2008 and EN ISO15223-1:2016.

Key to symbols used			
	Manufacturer		Expiration date
REF	Catalogue number		Date of manufacture
	Consult instructions for use	LOT	Batch code
	Temperature limitation	IVD	*In vitro* diagnostic medical device
	Sufficient for		Biological risk
CE	CE mark	EC REP	Authorized representative in the European Community

Please read this user manual carefully before operating to ensure proper use.

Version: WZK04-S-04

Getein Biotech, Inc.
Add: No.9 Bofu Road, Luhe District, Nanjing, 211505, China
Tel: +86-25-68568508
Fax: +86-25-68568500
E-mail: tech@getein.com.cn
overseas@getein.com.cn
Website: www.bio-GP.com.cn

Please contact Getein if you have any questions.

CERTIFICATE

EN ISO 13485:2016

DEKRA Certification GmbH hereby certifies that the organization

Analyticon Biotechnologies GmbH

Scope of certification:

Development, production and distribution of in-vitro diagnostics from the field of urine diagnostics for professional and near- patient applications
Distribution, service and installation of in-vitro-diagnostic analyzers from the field of urine diagnostics.
Distribution of in-vitro diagnostic devices from the field of hematology
Distribution and service of in-vitro-diagnostic analyzers from the field of hematology

Certified location:

Am Mühlenberg 10, 35104 Lichtenfels, Germany
(further locations see annex)

has established and maintains a quality management system according to the above mentioned standard.
The conformity was adduced with audit report no. 51519-R1-00.

Certificate registration no.:	51519-14-02_EN	Certificate valid from:	2023-03-06
Validity of previous certificate:	2023-03-05	Certificate valid to:	2025-01-10

Karin Leicht
DEKRA Certification GmbH, Stuttgart, 2023-03-06

DAkkS Deutsche Akkreditierungsstelle D-ZM-16029-08-00

Annex to the Certificate No. 51519-14-02

valid from 2023-03-06 to 2025-01-10

The following locations/companies belong to the certificate above:

	Headquarters		**Scope of certification**
	Analyticon Biotechnologies GmbH	Am Mühlenberg 10 35104 Lichtenfels Germany	see page 1
	at the following locations/at the companies at the following locations		**Scopes of certification**
1.		Am Teichsberg 10 Lichtenfels-Sachsenberg Germany	Reception, shipping and storage of raw materials, semi-finished goods, finished goods and analyzers from the fields of urine diagnostics and hematology.

Karin Leicht
DEKRA Certification GmbH, Stuttgart, 2023-03-06

Konformitätserklärung – Urin Diagnostik / Declaration of Conformity – Urine Diagnostics

Analyticon Biotechnologies GmbH

Am Mühlenberg 10,
35104 Lichtenfels, Germany

Wir erklären in alleiniger Verantwortung, dass die Medizinprodukte für die In-vitro-Diagnostik
We declare under our sole responsibility that the in vitro diagnostic medical devices

Bezeichnung und Artikelnummer: siehe Anhang
Description and article number: see annex

mit folgender Klassifizierung nach der Richtlinie über In-Vitro-Diagnostika 98/79/EG
classified as follows according to the directive on in vitro diagnostic medical devices 98/79/EC

( ) Produkt der Liste A, Anhang II / Device of List A, Annex II
( ) Produkt der Liste B, Anhang II / Device of List B, Annex II
( ) Produkt zur Eigenanwendung, das nicht in Anhang II genannt ist / *Device for self-testing not listed in Annex II*
(X) Sonstiges Produkt / *Other device*

allen Anforderungen der Richtlinie über In-vitro-Diagnostika 98/79/EG entspricht, die anwendbar sind.
meet all the provisions of the directive on in vitro diagnostic medical devices 98/79/EC which apply to it.

Konformitätsbewertungsverfahren *Conformity assessment procedure*	IVD 98/79/EG, Artikel 9 (1) und Anhang III / *IVD 98/79/EC Article 9 (1) and Annex III*
EDMA-Code und Registrierungsnummer *EDMS-Code and Registration-No.*	siehe Anhang *see annex*
Konformitätsbewertungsstelle *Notified Body (if consulted)*	nicht erforderlich, die Bewertung wurde in Eigenverantwortung des Herstellers durchgeführt *not applicable, evaluation was carried out under the manufacturer's own responsibility*

Ort, Datum / *Place, date*	Name und Funktion / *Name and function*
Lichtenfels, 18.01.2023	Dr. Jürgen Schmich (Direktor Qualitätssicherung / Director Quality Assurance)

Analyticon Biotechnologies GmbH
Am Mühlenberg 10,
35104 Lichtenfels, Germany

Anhang zur Konformitätserklärung – Urin Diagnostik /
Declaration of Conformity, Annex – Urine Diagnostics

CombiScreen Urine Controls

Name	REF	EDMS-Code	Reg.-Nr.
CombiScreen® Dip Check	93010	11.50.90.02.00	DE/CA30/00041388
CombiScreen® Drop Check	93015	11.50.90.02.00	DE/CA30/00041388

Konformitätserklärung – Urin Diagnostik / Declaration of Conformity – Urine Diagnostics

Analyticon Biotechnologies GmbH

Am Mühlenberg 10,
35104 Lichtenfels, Germany

Wir erklären in alleiniger Verantwortung, dass die Medizinprodukte für die In-vitro-Diagnostik
We declare under our sole responsibility that the in vitro diagnostic medical devices

Bezeichnung und Artikelnummer: siehe Anhang
Description and article number: see annex

mit folgender Klassifizierung nach der Richtlinie über In-Vitro-Diagnostika 98/79/EG
classified as follows according to the directive on in vitro diagnostic medical devices 98/79/EC

( ) Produkt der Liste A, Anhang II / Device of List A, Annex II
( ) Produkt der Liste B, Anhang II / Device of List B, Annex II
( ) Produkt zur Eigenanwendung, das nicht in Anhang II genannt ist / *Device for self-testing not listed in Annex II*
(X) Sonstiges Produkt / *Other device*

allen Anforderungen der Richtlinie über In-vitro-Diagnostika 98/79/EG entspricht, die anwendbar sind.
meet all the provisions of the directive on in vitro diagnostic medical devices 98/79/EC which apply to it.

Konformitätsbewertungsverfahren *Conformity assessment procedure*	IVD 98/79/EG, Artikel 9 (1) und Anhang III / *IVD 98/79/EC Article 9 (1) and Annex III*
EDMA-Code und Registrierungsnummer *EDMS-Code and Registration-No.*	siehe Anhang *see annex*
Konformitätsbewertungsstelle *Notified Body (if consulted)*	nicht erforderlich, die Bewertung wurde in Eigenverantwortung des Herstellers durchgeführt *not applicable, evaluation was carried out under the manufacturer's own responsibility*

Ort, Datum / *Place, date*	Name und Funktion / *Name and function*
Lichtenfels, 18.01.2023	Dr. Jürgen Schmich (Direktor Qualitätssicherung / Director Quality Assurance)

Analyticon Biotechnologies GmbH
Am Mühlenberg 10,
35104 Lichtenfels, Germany

Test strips visual and semi-automated systems

Name	REF	EDMS-Code	Reg.-Nr.
CombiScreen® 11SYS	93100	11.70.02.02.00	DE/CA30/00017200
CombiScreen® 11SYS	93150	11.70.02.02.00	DE/CA30/00017200
CombiScreen® 10SL	93120	11.70.02.02.00	DE/CA30/00017200
CombiScreen® 10SL	93120A	11.70.02.02.00	DE/CA30/00017200
CombiScreen® 10SL	93120B	11.70.02.02.00	DE/CA30/00017200
CombiScreen® 3	93108A	11.70.02.02.00	DE/CA30/00017200
CombiScreen® GAK	93107	11.70.02.02.00	DE/CA30/00017200
CombiScreen® GAK	93107A	11.70.02.02.00	DE/CA30/00017200
CombiScreen® GP	93104	11.70.02.02.00	DE/CA30/00017200
CombiScreen® GPK	93105	11.70.02.02.00	DE/CA30/00017200
CombiScreen® 11SYS PLUS	94100	11.70.02.02.00	DE/CA30/00017200
CombiScreen® 11SYS PLUS	94150	11.70.02.02.00	DE/CA30/00017200
CombiScreen® 11SYS PLUS	94150BC	11.70.02.02.00	DE/CA30/00017200
CombiScreen® 10SL PLUS	94120	11.70.02.02.00	DE/CA30/00017200
CombiScreen® 9 PLUS	94115	11.70.02.02.00	DE/CA30/00017200
CombiScreen® 9+Leuko PLUS	94250	11.70.02.02.00	DE/CA30/00017200
CombiScreen® 9+Leuko PLUS	94200	11.70.02.02.00	DE/CA30/00017200
CombiScreen® 7SYS PLUS	94110	11.70.02.02.00	DE/CA30/00017200
CombiScreen® 7SYS PLUS	94110A	11.70.02.02.00	DE/CA30/00017200
CombiScreen® 5SYS PLUS	94109	11.70.02.02.00	DE/CA30/00017200
CombiScreen® 5+Leuko PLUS	94517	11.70.02.02.00	DE/CA30/00017200
CombiScreen® 5+Leuko PLUS	94117	11.70.02.02.00	DE/CA30/00017200
CombiScreen® 5+N PLUS	94535	11.70.02.02.00	DE/CA30/00017200
CombiScreen® 5+N PLUS	94135	11.70.02.02.00	DE/CA30/00017200
CombiScreen® 3 PLUS	94508	11.70.02.02.00	DE/CA30/00017200
CombiScreen® 3 PLUS	94108	11.70.02.02.00	DE/CA30/00017200
CombiScreen® Glu PLUS	94501	11.70.02.02.00	DE/CA30/00017200
CombiScreen® Nitrit PLUS	94506	11.70.02.02.00	DE/CA30/00017200
CombiScreen® mALB / CREA	94025	11.70.02.02.00	DE/CA30/00017200

/ 77 ELEKTRONIKA KFT.
H-1116 Budapest, Fehérvári út 98.

EU-DECLARATION OF CONFORMITY

Manufacturer name:	**77 Elektronika Műszeripari Kft.**
Address:	Fehérvári út 98., H-1116 Budapest
SRN number:	HU-MF-000004266

Product(s) name:	**Urilyzer Cell Cuvettes**
Reference number:	ULC001
Basic UDI-DI:	59973457CUV9W
GMDN / EMDN	61032 / W02010785
Intended purpose of the device:	Urilyzer Cell Cuvettes are disposable, single use polycarbonate specimen receptacles used to analyse uncentrifuged, human urine samples with Urilyzer Cell urine sediment analysers. It is intended for professional, laboratory use. It is intended for in vitro diagnostic use.
Classification:	A class

The manufacturer declares under its sole responsibility that the above-mentioned product complies with the requirements of the following legislation (s):

Applicable legalisations:	Regulation (EU) 2017/746 of 5 April 2017 on in vitro diagnostic medical devices

Notified Body name:	N/A
Notified Body address:	N/A
Notified Body Identification Number:	N/A
Conformity assessment procedure:	N/A
EC Certificate of conformity's type, number and validity:	N/A

Budapest, 25.05.2022.

.....

Oliver Babinszki
Quality and Environmental Management Director

77 Elektronika Műszeripari Kft.
1116 Budapest, Fehérvári út 98.
Adószám: 10229064-2-44
BBRT: 10102093-01196703-00000005
36.

Authorization Certificate

analyticon

Vitalie Goreacii

SANMEDICO SRL

This is to certify that the above named general manager has successfully completed the full application and technical training which was specifically prepared and carried out on the Analyticon Biotechnologies GmbH equipment mentioned below on May 22nd to 23rd, 2023

Urilyzer® Cell

We hereby state that the general manager is authorized and qualified by Analyticon to do installation, operation, user and technical training, service and maintenance of the equipment listed above.

Analyticon
Biotechnologies GmbH
Customer Support & Trainings

Analyticon Biotechnologies GmbH · Germany · Lichtenfels · 35104 · Mühlenberg 10 · analyticon

Nathalie Mütze
Manager Customer Support

Nils Albrecht
Customer Support

CS_FB_OR_9999

Certificate

TÜVRheinland®

Quality Management System
EN ISO 13485:2016

Registration No.: SX 1006099-1

Organization: 77 Elektronika Műszeripari Kft.
Fehérvári út 98.
1116 Budapest
Hungary

Scope: Design and development, production, distribution, installation and servicing of blood glucose measuring systems, urine analyzers and rapid test readers, including related consumables.

The Certification Body of TÜV Rheinland LGA Products GmbH certifies that the organization has established and applies a quality management system for medical devices.
Proof has been furnished that the requirements specified in the abovementioned standard are fulfilled. The quality management system is subject to yearly surveillance.

Report No.: 93389457-30
Effective date: 2022-11-18
Expiry date: 2025-11-17
Issue date: 2022-11-09

TÜV Rheinland LGA Products GmbH TÜVRheinland Zertifizierungsstelle

Rafał Byczkowski
TÜV Rheinland LGA Products GmbH
Tillystraße 2 · 90431 Nürnberg · Germany

DAkkS Deutsche Akkreditierungsstelle D-ZM-14169-01-02

Certificate

TÜVRheinland®

Quality Management System
EN ISO 13485:2016

Registration No.: SX 1006099-1

Organization: 77 Elektronika Műszeripari Kft.
Fehérvári út 98.
1116 Budapest
Hungary

The scope of certification includes the following additional sites:

No.	Facility	Scope
/01	Elektronika Műszeripari Kft. Fehérvári út 98. 1116 Budapest Hungary	Design and development, production, distribution, installation and servicing.
/02	77 Elektronika Műszeripari Kft. Telephely Sztregova utca 1 1116 Budapest Hungary	Manufacture and warehouse of blood glucose measuring systems, urine analyzers, related consumables and parts. Manufacturing of SMT technology.

Report No.: 93389457-30
Effective date: 2022-11-18
Expiry date: 2025-11-17
Issue date: 2022-11-09

TÜV Rheinland LGA Products GmbH TÜVRheinland® Zertifizierungsstelle

Rafał Byczkowski
TÜV Rheinland LGA Products GmbH
Tillystraße 2 · 90431 Nürnberg · Germany

DAkkS Deutsche Akkreditierungsstelle D-ZM-14169-01-02

For submission at the competent Authorities of the Republic of Moldova

analyticon®

Letter of Authorization

WHEREAS, **Analyticon Biotechnologies GmbH**, who is an established, and well-known manufacturer and producer of Medical Diagnostics having production facilities at 35104 Lichtenfels (Germany), Am Muehlenberg 10, do hereby declare that

Sanmedico SRL
A. Corobceanu street 7A, apt. 9, Chişinău MD-2012, Moldova
Tel: +373 60 15-57-88
E-Mail: sanmedico.office@gmail.com

is authorized to register, import, promote and sell our urinalysis and hematology products non-exclusively within the territory of the Republic of Moldova as a Distributor for our products. We authorize Sanmedico SRL to overtake the procedures regarding the registration of the mentioned products and the Renewal of expiring Licenses for Sale of our product range of these In-Vitro-Diagnostic products at the Authorities of the Republic of Moldova. Sanmedico SRL is authorized to participate in tenders only in the territory of the Republic of Moldova. This Letter of Authorization is valid for three (3) years from the date of issue. It could be elongated from Analyticon Biotechnologies AG for another period in accordance with Sanmedico SRL. Cancellation must be in writing with a cancellation period of 3 Months for each party.

The construction of this agreement, validity and performance of this agreement and all subsequent agreements shall be exclusively governed by the laws of Germany. This agreement shall be interpreted under German Law. The laws of the Federal Republic of Germany are legally binding; this excludes the validity of the UN purchasing laws, particularly the United Nations treaty on contracts regarding the international sale of moveable property. This is also valid should the DISTRIBUTOR not be of German nationality or his head office be situated outside Germany. The parties submit to the exclusive jurisdiction of the District Courts at Korbach, Postal Code D-34497, Germany / the regional court of the city of Kassel, Germany. This Authorisation letter will replace all other existing Authorisation letters between the parties.

For and on behalf of Analyticon Biotechnologies GmbH
Signed on 14th June 2023, at Lichtenfels (Germany)

Analyticon Biotechnologies GmbH · Am Muehlenberg 10 · 35104 Lichtenfels · Germany

Dennis Kasper
Business Area Manager Europe (East) & Africa
Analyticon Biotechnologies GmbH

Safety Data Sheet

according to Regulation (EC) No 1907/2006

CombiScreen® Drop Check Level 2

SECTION 1: Identification of the substance/mixture and of the company/undertaking

1.1. Product identifier

CombiScreen® Drop Check Level 2

Product group: Endprodukt / Endproduct

1.2. Relevant identified uses of the substance or mixture and uses advised against

1.3. Details of the supplier of the safety data sheet

Company name: Analyticon® Biotechnologies GmbH
Street: Am Mühlenberg 10
Place: D-35104 Lichtenfels
Telephone: +49 (0) 6454/7991-0 Telefax: +49 (0) 6454/7991-30
E-mail: [redacted]
Contact person: Zentrale Telephone: +49 (0) 6454/7991-0
Internet: [redacted]

1.4. Emergency telephone number:

Zentrale: +49 (0) 6454/7991-0

SECTION 2: Hazards identification

2.1. Classification of the substance or mixture

Regulation (EC) No 1272/2008

This mixture is not classified as hazardous in accordance with Regulation (EC) No 1272/2008.

The mixture is classified as not hazardous according to regulation (EC) No 1272/2008 [CLP].

2.2. Label elements

Regulation (EC) No 1272/2008

Special labelling of certain mixtures

Restricted to professional users.

SECTION 3: Composition/information on ingredients

3.2. Mixtures

Hazardous components

CAS No	Chemical name			Quantity
	EC No	Index No	REACH No	
	Classification (Regulation (EC) No 1272/2008)			
	Human Source Material			10-60 %

Full text of H and EUH statements: see section 16.

Further Information

The mixture is classified as not hazardous according to regulation (EC) No 1272/2008 [CLP].

SECTION 4: First aid measures

4.1. Description of first aid measures

After inhalation

Provide fresh air.

After contact with skin

Wash with plenty of water. Take off contaminated clothing and wash it before reuse.

After contact with eyes

Rinse immediately carefully and thoroughly with eye-bath or water.

After ingestion

Rinse mouth immediately and drink plenty of water.
Rinse mouth thoroughly with water.
Seek medical advice immediately.

4.2. Most important symptoms and effects, both acute and delayed

No information available.

4.3. Indication of any immediate medical attention and special treatment needed

Treat symptomatically.

SECTION 5: Firefighting measures

5.1. Extinguishing media

Suitable extinguishing media

Co-ordinate fire-fighting measures to the fire surroundings.
The product itself does not burn.

5.2. Special hazards arising from the substance or mixture

Non-flammable.

5.3. Advice for firefighters

In case of fire: Wear self-contained breathing apparatus.

SECTION 6: Accidental release measures

6.1. Personal precautions, protective equipment and emergency procedures

General advice

Wear breathing apparatus if exposed to vapours/dusts/aerosols.

6.2. Environmental precautions

Do not allow to enter into surface water or drains.
Prevent spread over a wide area (e.g. by containment or oil barriers).
Do not allow to enter into soil/subsoil.

6.3. Methods and material for containment and cleaning up

Other information

Take up mechanically. Treat the recovered material as prescribed in the section on waste disposal.
Take up dust-free and set down dust-free.

6.4. Reference to other sections

Safe handling: see section 7
Personal protection equipment: see section 8
Disposal: see section 13

SECTION 7: Handling and storage

7.1. Precautions for safe handling

Advice on safe handling

Use only in well-ventilated areas.
The floor should be leak tight, jointless and not absorbent.
All work processes must always be designed so that the following is excluded:

Advice on protection against fire and explosion

Usual measures for fire prevention.
When using do not smoke.

Advice on general occupational hygiene

Take off contaminated clothing. Wash hands before breaks and after work. When using do not eat or drink.

Wash hands before breaks and after work.

Further information on handling

When using do not eat, drink, smoke, sniff.

7.2. Conditions for safe storage, including any incompatibilities

Requirements for storage rooms and vessels

Keep container tightly closed.

Keep only in the original container in a cool, well-ventilated place.

Further information on storage conditions

2 8

Protect against:

SECTION 8: Exposure controls/personal protection

8.1. Control parameters

8.2. Exposure controls

Individual protection measures, such as personal protective equipment

Eye/face protection

Wear eye/face protection.

Hand protection

When handling with chemical substances, protective gloves must be worn with the CE-label including the four control digits. The quality of the protective gloves resistant to chemicals must be chosen as a function of the specific working place concentration and quantity of hazardous substances. For special purposes, it is recommended to check the resistance to chemicals of the protective gloves mentioned above together with the supplier of these gloves. EN ISO 374

Breakthrough times and swelling properties of the material must be taken into consideration.

Skin protection

Wear suitable protective clothing. Suitable protective clothing:

Respiratory protection

In case of inadequate ventilation wear respiratory protection. Respiratory protection necessary at:

SECTION 9: Physical and chemical properties

9.1. Information on basic physical and chemical properties

Physical state:		
Colour:		
Odour:	characteristic	
Melting point/freezing point:		not determined
Boiling point or initial boiling point and boiling range:		not determined
Flammability:		not determined not applicable

Lower explosion limits:	not determined
Upper explosion limits:	not determined
Decomposition temperature:	not determined
Partition coefficient n-octanol/water:	not determined
Vapour pressure:	not determined
Density:	not determined
Relative vapour density:	not determined

9.2. Other information

Information with regard to physical hazard classes

Explosive properties

The study does not need to be conducted because there are no chemical groups associated with explosive properties present in the molecule.

Self-ignition temperature

Solid:	not determined
Gas:	not applicable

Other safety characteristics

Evaporation rate:	not determined
Solid content:	not determined

SECTION 10: Stability and reactivity

10.1. Reactivity

No hazardous reaction when handled and stored according to provisions.

10.2. Chemical stability

The product is stable under storage at normal ambient temperatures.

10.3. Possibility of hazardous reactions

No known hazardous reactions.

10.4. Conditions to avoid

May cause decomposition by long-term light influence.

10.5. Incompatible materials

No information available.

SECTION 11: Toxicological information

11.1. Information on hazard classes as defined in Regulation (EC) No 1272/2008

Acute toxicity

No information available.

ATEmix calculated

ATE (oral) > 2000 mg/kg; ATE (dermal) > 2000 mg/kg; ATE (inhalation vapour) > 20 mg/l; ATE (inhalation dust/mist) > 5 mg/l

Sensitising effects

No information available.

STOT-repeated exposure

No information available.

Specific effects in experiment on an animal

No information available.

Additional information on tests

The mixture is classified as not hazardous according to Directive 1999/45/EC.

11.2. Information on other hazards

Endocrine disrupting properties

No information available.

SECTION 12: Ecological information

12.1. Toxicity

The product has not been tested.

12.2. Persistence and degradability

No data available

12.3. Bioaccumulative potential

No data available

12.4. Mobility in soil

No data available

12.5. Results of PBT and vPvB assessment

The substances in the mixture do not meet the PBT/vPvB criteria according to REACH, annex XIII.
The product has not been tested.

12.6. Endocrine disrupting properties

This product does not contain a substance that has endocrine disrupting properties with respect to non-target organisms as no components meets the criteria.

12.7. Other adverse effects

No data available

Further information

Avoid release to the environment.

SECTION 13: Disposal considerations

13.1. Waste treatment methods

Disposal recommendations

Dispose of waste according to applicable legislation. Dispose of waste according to applicable legislation.
Dispose of waste according to "Kreislaufwirtschafts- und Abfallgesetz (KrW-/AbfG)".

List of Wastes Code - residues/unused products

160506 WASTES NOT OTHERWISE SPECIFIED IN THE LIST; gases in pressure containers and discarded chemicals; laboratory chemicals, consisting of or containing hazardous substances, including mixtures of laboratory chemicals; hazardous waste

List of Wastes Code - used product

160506 WASTES NOT OTHERWISE SPECIFIED IN THE LIST; gases in pressure containers and discarded chemicals; laboratory chemicals, consisting of or containing hazardous substances, including mixtures of laboratory chemicals; hazardous waste

List of Wastes Code - contaminated packaging

150106 WASTE PACKAGING; ABSORBENTS, WIPING CLOTHS, FILTER MATERIALS AND PROTECTIVE CLOTHING NOT OTHERWISE SPECIFIED; packaging (including separately collected municipal packaging waste); mixed packaging

Contaminated packaging

Wash with plenty of water. Completely emptied packages can be recycled.

SECTION 14: Transport information

Land transport (ADR/RID)

14.1. UN number or ID number:	No dangerous good in sense of this transport regulation.
14.2. UN proper shipping name:	No dangerous good in sense of this transport regulation.
14.3. Transport hazard class(es):	No dangerous good in sense of this transport regulation.
14.4. Packing group:	No dangerous good in sense of this transport regulation.

Inland waterways transport (ADN)

14.1. UN number or ID number:	No dangerous good in sense of this transport regulation.
14.2. UN proper shipping name:	No dangerous good in sense of this transport regulation.
14.3. Transport hazard class(es):	No dangerous good in sense of this transport regulation.
14.4. Packing group:	No dangerous good in sense of this transport regulation.

Marine transport (IMDG)

14.1. UN number or ID number:	No dangerous good in sense of this transport regulation.
14.2. UN proper shipping name:	No dangerous good in sense of this transport regulation.
14.3. Transport hazard class(es):	No dangerous good in sense of this transport regulation.
14.4. Packing group:	No dangerous good in sense of this transport regulation.

Air transport (ICAO-TI/IATA-DGR)

14.1. UN number or ID number:	No dangerous good in sense of this transport regulation.
14.2. UN proper shipping name:	No dangerous good in sense of this transport regulation.
14.3. Transport hazard class(es):	No dangerous good in sense of this transport regulation.
14.4. Packing group:	No dangerous good in sense of this transport regulation.

14.5. Environmental hazards

ENVIRONMENTALLY HAZARDOUS: No

14.6. Special precautions for user

No dangerous good in sense of this transport regulation.

14.7. Maritime transport in bulk according to IMO instruments

No dangerous good in sense of this transport regulation.

SECTION 15: Regulatory information

15.1. Safety, health and environmental regulations/legislation specific for the substance or mixture

National regulatory information

Water hazard class (D): - - non-hazardous to water

15.2. Chemical safety assessment

Chemical safety assessments for substances in this mixture were not carried out.

SECTION 16: Other information

Changes

This data sheet contains changes from the previous version in section(s): 2,11.

Abbreviations and acronyms

ADR: Accord européen sur le transport des marchandises dangereuses par Route
(European Agreement concerning the International Carriage of Dangerous Goods by Road)
IMDG: International Maritime Code for Dangerous Goods
IATA: International Air Transport Association
GHS: Globally Harmonized System of Classification and Labelling of Chemicals
EINECS: European Inventory of Existing Commercial Chemical Substances
ELINCS: European List of Notified Chemical Substances
CAS: Chemical Abstracts Service
LC50: Lethal concentration, 50%
LD50: Lethal dose, 50%

Further Information

The information is based on the present level of our knowledge. It does not, however, give assurance of product properties and establishes no contract legal rights. The receiver of our product is singularly responsible for adhering to existing laws and regulations. The above information describes exclusively the safety requirements of the product and is based on our present-day knowledge. The information is intended to give you advice about the safe handling of the product named in this safety data sheet, for storage, processing,

transport and disposal. The information cannot be transferred to other products. In the case of mixing the product with other products or in the case of processing, the information on this safety data sheet is not necessarily valid for the new made-up material.
The information is based on the present level of our knowledge. It does not, however, give assurance of product properties and establishes no contract legal rights.
The receiver of our product is singularly responsible for adhering to existing laws and regulations.

(The data for the hazardous ingredients were taken respectively from the last version of the sub-contractor's safety data sheet.)

Safety Data Sheet

according to Regulation (EC) No 1907/2006

CombiScreen® 11SYS

SECTION 1: Identification of the substance/mixture and of the company/undertaking

1.1. Product identifier

CombiScreen® 11SYS

Product group: Endprodukt / Endproduct

1.2. Relevant identified uses of the substance or mixture and uses advised against

1.3. Details of the supplier of the safety data sheet

Company name: Analyticon® Biotechnologies GmbH
Street: Am Mühlenberg 10
Place: D-35104 Lichtenfels
Telephone: +49 (0) 6454/7991-0 Telefax: +49 (0) 6454/7991-30
E-mail: [redacted]
Contact person: Zentrale Telephone: +49 (0) 6454/7991-0
Internet: [redacted]

1.4. Emergency telephone number: Zentrale: +49 (0) 6454/7991-0

SECTION 2: Hazards identification

2.1. Classification of the substance or mixture

Regulation (EC) No 1272/2008

This mixture is not classified as hazardous in accordance with Regulation (EC) No 1272/2008.

2.2. Label elements

SECTION 3: Composition/information on ingredients

3.2. Mixtures

Hazardous components

none (according to Regulation (EC) No 1907/2006 (REACH))

SECTION 4: First aid measures

4.1. Description of first aid measures

After inhalation

Provide fresh air.

After contact with skin

Wash with plenty of water. Take off contaminated clothing and wash it before reuse.

After contact with eyes

Rinse immediately carefully and thoroughly with eye-bath or water.

After ingestion

Rinse mouth thoroughly with water.
Seek medical advice immediately.

4.2. Most important symptoms and effects, both acute and delayed

No information available.

4.3. Indication of any immediate medical attention and special treatment needed

Treat symptomatically.

SECTION 5: Firefighting measures

5.1. Extinguishing media

Suitable extinguishing media

Co-ordinate fire-fighting measures to the fire surroundings. The product itself does not burn.

5.2. Special hazards arising from the substance or mixture

Non-flammable.

5.3. Advice for firefighters

In case of fire: Wear self-contained breathing apparatus.

Additional information

Collect contaminated fire extinguishing water separately. Do not allow entering drains or surface water.

SECTION 6: Accidental release measures

6.1. Personal precautions, protective equipment and emergency procedures

General advice

Avoid dust formation.

Wear breathing apparatus if exposed to vapours/dusts/aerosols.

6.2. Environmental precautions

Do not allow to enter into surface water or drains.

Prevent spread over a wide area (e.g. by containment or oil barriers).

Do not allow to enter into soil/subsoil.

6.3. Methods and material for containment and cleaning up

Other information

Take up mechanically. Treat the recovered material as prescribed in the section on waste disposal. Take up dust-free and set down dust-free.

6.4. Reference to other sections

Safe handling: see section 7

Personal protection equipment: see section 8

Disposal: see section 13

SECTION 7: Handling and storage

7.1. Precautions for safe handling

Advice on safe handling

Use only in well-ventilated areas.

The floor should be leak tight, jointless and not absorbent.

All work processes must always be designed so that the following is excluded:

Advice on protection against fire and explosion

Usual measures for fire prevention.

When using do not smoke.

Advice on general occupational hygiene

Take off contaminated clothing. When using do not eat or drink. Wash hands before breaks and after work.

Further information on handling

When using do not eat, drink, smoke, sniff.

7.2. Conditions for safe storage, including any incompatibilities

Requirements for storage rooms and vessels

Keep container tightly closed. Keep only in the original container in a cool, well-ventilated place.

Further information on storage conditions

15 25

Protect against:

SECTION 8: Exposure controls/personal protection

8.1. Control parameters

Occupational exposure limit values

CAS No	Name of agent	ppm	mg/m³	fib/cm³	Category	Origin
7664-38-2	Orthophosphoric acid	-	1		TWA (8 h)	
		-	2		STEL (15 min)	

8.2. Exposure controls

Individual protection measures, such as personal protective equipment

Eye/face protection

Wear eye/face protection.

Hand protection

When handling with chemical substances, protective gloves must be worn with the CE-label including the four control digits. The quality of the protective gloves resistant to chemicals must be chosen as a function of the specific working place concentration and quantity of hazardous substances. For special purposes, it is recommended to check the resistance to chemicals of the protective gloves mentioned above together with the supplier of these gloves. EN ISO 374

Breakthrough times and swelling properties of the material must be taken into consideration.

Skin protection

Wear suitable protective clothing.

Respiratory protection

Respiratory protection necessary at:

SECTION 9: Physical and chemical properties

9.1. Information on basic physical and chemical properties

Physical state:		
Colour:		
Odour:	characteristic	
Melting point/freezing point:		not determined
Boiling point or initial boiling point and boiling range:		not determined
Flammability:		not determined not applicable
Lower explosion limits:		not determined
Upper explosion limits:		not determined
Decomposition temperature:		not determined
pH-Value:		No data available
Water solubility:		The study does not need to be conducted because the substance is known to be insoluble in water.
Solubility in other solvents		
Buffer		
Partition coefficient n-octanol/water:		not determined
Vapour pressure:		not determined
Density:		not determined
Relative vapour density:		not determined

9.2. Other information

Information with regard to physical hazard classes

Explosive properties

The study does not need to be conducted because there are no chemical groups associated with explosive properties present in the molecule.

Self-ignition temperature

Solid:	not determined
Gas:	not applicable

Other safety characteristics

Evaporation rate:	not determined
Solid content:	not determined

SECTION 10: Stability and reactivity

10.1. Reactivity

No hazardous reaction when handled and stored according to provisions.

10.2. Chemical stability

The product is stable under storage at normal ambient temperatures.

10.3. Possibility of hazardous reactions

No known hazardous reactions.

10.4. Conditions to avoid

May cause decomposition by long-term light influence.

10.5. Incompatible materials

No information available.

SECTION 11: Toxicological information

11.1. Information on hazard classes as defined in Regulation (EC) No 1272/2008

Acute toxicity

No information available.

ATEmix calculated

ATE (oral) > 2000 mg/kg; ATE (dermal) > 2000 mg/kg; ATE (inhalation vapour) > 20 mg/l; ATE (inhalation dust/mist) > 5 mg/l

Irritation and corrosivity

No information available.

Sensitising effects

No information available.

Carcinogenic/mutagenic/toxic effects for reproduction

No information available.

STOT-repeated exposure

No information available.

Specific effects in experiment on an animal

No information available.

Additional information on tests

The mixture is classified as not hazardous according to regulation (EC) No 1272/2008 [CLP].

11.2. Information on other hazards

Endocrine disrupting properties

No information available.

SECTION 12: Ecological information

12.1. Toxicity

The product has not been tested.

12.2. Persistence and degradability

The product has not been tested.

12.3. Bioaccumulative potential

The product has not been tested.

12.4. Mobility in soil

The product has not been tested.

12.5. Results of PBT and vPvB assessment

The substances in the mixture do not meet the PBT/vPvB criteria according to REACH, annex XIII.

12.6. Endocrine disrupting properties

This product does not contain a substance that has endocrine disrupting properties with respect to non-target organisms as no components meets the criteria.

12.7. Other adverse effects

The product has not been tested.

Further information

Do not allow to enter into surface water or drains. Do not allow to enter into soil/subsoil.

SECTION 13: Disposal considerations

13.1. Waste treatment methods

Disposal recommendations

Do not allow to enter into surface water or drains. Do not allow to enter into soil/subsoil. Dispose of waste according to applicable legislation.
Dispose of waste according to "Kreislaufwirtschafts- und Abfallgesetz (KrW-/AbfG)".

Contaminated packaging

Non-contaminated packages may be recycled. Handle contaminated packages in the same way as the substance itself.

SECTION 14: Transport information

Land transport (ADR/RID)

Other applicable information (land transport)

No dangerous good in sense of this transport regulation.

Inland waterways transport (ADN)

Other applicable information (inland waterways transport)

No dangerous good in sense of this transport regulation.

Marine transport (IMDG)

Other applicable information (marine transport)

No dangerous good in sense of this transport regulation.

Air transport (ICAO-TI/IATA-DGR)

Other applicable information (air transport)

No dangerous good in sense of this transport regulation.

14.5. Environmental hazards

ENVIRONMENTALLY HAZARDOUS: No

14.6. Special precautions for user

No information available.

14.7. Maritime transport in bulk according to IMO instruments

not applicable

SECTION 15: Regulatory information

15.1. Safety, health and environmental regulations/legislation specific for the substance or mixture

EU regulatory information

Restrictions on use (REACH, annex XVII):

Entry 75

2004/42/EC (VOC): 0,009 %

National regulatory information

Water hazard class (D): - - non-hazardous to water

15.2. Chemical safety assessment

Chemical safety assessments for substances in this mixture were not carried out.

SECTION 16: Other information

Changes

This data sheet contains changes from the previous version in section(s): 11.

Abbreviations and acronyms

ADR: Accord européen sur le transport des marchandises dangereuses par Route
(European Agreement concerning the International Carriage of Dangerous Goods by Road)
IMDG: International Maritime Code for Dangerous Goods
IATA: International Air Transport Association
GHS: Globally Harmonized System of Classification and Labelling of Chemicals
EINECS: European Inventory of Existing Commercial Chemical Substances
ELINCS: European List of Notified Chemical Substances
CAS: Chemical Abstracts Service
LC50: Lethal concentration, 50%
LD50: Lethal dose, 50%
Skin Corr: Skin corrosion

Further Information

The above information describes exclusively the safety requirements of the product and is based on our present-day knowledge. The information is intended to give you advice about the safe handling of the product named in this safety data sheet, for storage, processing, transport and disposal. The information cannot be transferred to other products. In the case of mixing the product with other products or in the case of processing, the information on this safety data sheet is not necessarily valid for the new made-up material.

(The data for the hazardous ingredients were taken respectively from the last version of the sub-contractor's safety data sheet.)

Urilyzer Cell Cuvettes

REF

ULC001

Instructions for use

Intended use:

Urilyzer Cell Cuvettes are disposable, single use polycarbonate specimen receptacles used to analyse uncentrifuged, human urine samples with Urilyzer Cell urine sediment analysers. It is intended for professional, laboratory use. It is intended for in vitro diagnostic use.

Test principle:

Urilyzer Cell Cuvettes are specimen receptacles allowing for microscopic analysis of urine samples.

Materials not provided:

- Urilyzer Cell urine sediment analyzer
- General laboratory equipment

Using cuvettes:



1. Place the cuvette holder in your analyzer

2. Remove the closing tape of the cuvette holder

Environmental Conditions

Storage temperature	0 – 45°C
Transportation temperature	-25°C – 60°C
Transportation humidity	20 – 80 %
Operation temperature	5°C – 40°C
Operational humidity	20 – 80 %

Warnings and cautions

- Do not store cuvettes in direct sunlight
- Do not remove closing tape from the cuvette holder before installing in your analyzer
- Do not remove partially full cuvette holders from your analyzer
- Each cuvette is single use, never perform a test with previously used cuvette
- Since urine is a fluid of human origin, it may be infectious and may bear the possibility of biological risks
- Handle used Urilyzer Cell Cuvettes and urine contaminants with care
- Dispose of waste according to accepted laboratory instructions and procedures
- Use cuvettes before expiration date

Check your analysers instructions for use for details on specimen collection, potential preparatory steps, result calculation, analytical and performance characteristics, interferences, limitations, quality control procedures, specific warnings and cautions

Incident reporting

Inform your Analyticon Biotechnologies service representative and your local competent authority about any serious incidents which may occur when using this product.

Symbols:

UDI Unique Device Identifier

IVD In vitro diagnostic medical device

REF Catalogue Number

LOT Lot Number

CE The CE mark identifies that the product complies with the applicable directives of the EuropeanUnion

Use by

0°C +45°C Temperature Limitation

Manufacturer

Keep away from sunlight

Consult instructions for use

20% 80% Humidity limitation

Caution

Σ 600 Contents sufficient for 600 tests

Do NOT Reuse

HU Country of origin and manufacturing date

Distributed by

Version history

Version	Date	Changes
1	2022.04.12.	First release

CE

Manufacturer:

77 Elektronika Kft.

98. Fehérvári út, 1116 Budapest
HUNGARY
www.en.e77.hu
sales@e77.hu
Tel: + 36 1 206 - 1480
Fax: + 36 1 206 - 1481

Distributed by:

Analyticon Biotechnologies GmbH

Am Muehlenberg 10
35104 Lichtenfels, Germany
info@analyticon-diagnostics.com
www.analyticon-diagnostics.com

Safety Data Sheet

according to Regulation (EC) No 1907/2006

CombiScreen® Drop Check Level 1

SECTION 1: Identification of the substance/mixture and of the company/undertaking

1.1. Product identifier

CombiScreen® Drop Check Level 1

Product group: Endprodukt / Endproduct

1.2. Relevant identified uses of the substance or mixture and uses advised against

1.3. Details of the supplier of the safety data sheet

Company name: Analyticon® Biotechnologies GmbH
Street: Am Mühlenberg 10
Place: D-35104 Lichtenfels
Telephone: +49 (0) 6454/7991-0 Telefax: +49 (0) 6454/7991-30
E-mail: [redacted]
Contact person: Zentrale Telephone: +49 (0) 6454/7991-0
Internet: [redacted]

1.4. Emergency telephone number:

Zentrale: +49 (0) 6454/7991-0

SECTION 2: Hazards identification

2.1. Classification of the substance or mixture

Regulation (EC) No 1272/2008

This mixture is not classified as hazardous in accordance with Regulation (EC) No 1272/2008.

The mixture is classified as not hazardous according to regulation (EC) No 1272/2008 [CLP].

2.2. Label elements

Regulation (EC) No 1272/2008

Special labelling of certain mixtures

Restricted to professional users.

SECTION 3: Composition/information on ingredients

3.2. Mixtures

Hazardous components

CAS No	Chemical name			Quantity
	EC No	Index No	REACH No	
	Classification (Regulation (EC) No 1272/2008)			
	Human Source Material			10-60 %

Full text of H and EUH statements: see section 16.

Further Information

The mixture is classified as not hazardous according to regulation (EC) No 1272/2008 [CLP].

SECTION 4: First aid measures

4.1. Description of first aid measures

After inhalation

Provide fresh air.

After contact with skin

Wash with plenty of water. Take off contaminated clothing and wash it before reuse.

After contact with eyes

Rinse immediately carefully and thoroughly with eye-bath or water.

After ingestion

Rinse mouth immediately and drink plenty of water.
Rinse mouth thoroughly with water.
Seek medical advice immediately.

4.2. Most important symptoms and effects, both acute and delayed

No information available.

4.3. Indication of any immediate medical attention and special treatment needed

Treat symptomatically.

SECTION 5: Firefighting measures

5.1. Extinguishing media

Suitable extinguishing media

Co-ordinate fire-fighting measures to the fire surroundings.
The product itself does not burn.

5.2. Special hazards arising from the substance or mixture

Non-flammable.

5.3. Advice for firefighters

In case of fire: Wear self-contained breathing apparatus.

SECTION 6: Accidental release measures

6.1. Personal precautions, protective equipment and emergency procedures

General advice

Wear breathing apparatus if exposed to vapours/dusts/aerosols.

6.2. Environmental precautions

Do not allow to enter into surface water or drains.
Prevent spread over a wide area (e.g. by containment or oil barriers).
Do not allow to enter into soil/subsoil.

6.3. Methods and material for containment and cleaning up

Other information

Take up mechanically. Treat the recovered material as prescribed in the section on waste disposal.
Take up dust-free and set down dust-free.

6.4. Reference to other sections

Safe handling: see section 7
Personal protection equipment: see section 8
Disposal: see section 13

SECTION 7: Handling and storage

7.1. Precautions for safe handling

Advice on safe handling

Use only in well-ventilated areas.
The floor should be leak tight, jointless and not absorbent.
All work processes must always be designed so that the following is excluded:

Advice on protection against fire and explosion

Usual measures for fire prevention.
When using do not smoke.

Advice on general occupational hygiene

Take off contaminated clothing. Wash hands before breaks and after work. When using do not eat or drink.

Wash hands before breaks and after work.

Further information on handling

When using do not eat, drink, smoke, sniff.

7.2. Conditions for safe storage, including any incompatibilities

Requirements for storage rooms and vessels

Keep container tightly closed.

Keep only in the original container in a cool, well-ventilated place.

Further information on storage conditions

2 8

Protect against:

SECTION 8: Exposure controls/personal protection

8.1. Control parameters

8.2. Exposure controls

Individual protection measures, such as personal protective equipment

Eye/face protection

Wear eye/face protection.

Hand protection

When handling with chemical substances, protective gloves must be worn with the CE-label including the four control digits. The quality of the protective gloves resistant to chemicals must be chosen as a function of the specific working place concentration and quantity of hazardous substances. For special purposes, it is recommended to check the resistance to chemicals of the protective gloves mentioned above together with the supplier of these gloves. EN ISO 374

Breakthrough times and swelling properties of the material must be taken into consideration.

Skin protection

Wear suitable protective clothing. Suitable protective clothing:

Respiratory protection

In case of inadequate ventilation wear respiratory protection. Respiratory protection necessary at:

SECTION 9: Physical and chemical properties

9.1. Information on basic physical and chemical properties

Physical state:		
Colour:		
Odour:	characteristic	
Melting point/freezing point:		not determined
Boiling point or initial boiling point and boiling range:		not determined
Flammability:		not determined not applicable

Lower explosion limits:	not determined
Upper explosion limits:	not determined
Decomposition temperature:	not determined
Partition coefficient n-octanol/water:	not determined
Vapour pressure:	not determined
Density:	not determined
Relative vapour density:	not determined

9.2. Other information

Information with regard to physical hazard classes

Explosive properties

The study does not need to be conducted because there are no chemical groups associated with explosive properties present in the molecule.

Self-ignition temperature

Solid:	not determined
Gas:	not applicable

Other safety characteristics

Evaporation rate:	not determined
Solid content:	not determined

SECTION 10: Stability and reactivity

10.1. Reactivity

No hazardous reaction when handled and stored according to provisions.

10.2. Chemical stability

The product is stable under storage at normal ambient temperatures.

10.3. Possibility of hazardous reactions

No known hazardous reactions.

10.4. Conditions to avoid

May cause decomposition by long-term light influence.

10.5. Incompatible materials

No information available.

SECTION 11: Toxicological information

11.1. Information on hazard classes as defined in Regulation (EC) No 1272/2008

Acute toxicity

No information available.

ATEmix calculated

ATE (oral) > 2000 mg/kg; ATE (dermal) > 2000 mg/kg; ATE (inhalation vapour) > 20 mg/l; ATE (inhalation dust/mist) > 5 mg/l

Sensitising effects

No information available.

STOT-repeated exposure

No information available.

Specific effects in experiment on an animal

No information available.

Additional information on tests

The mixture is classified as not hazardous according to Directive 1999/45/EC.

11.2. Information on other hazards

Endocrine disrupting properties

No information available.

SECTION 12: Ecological information

12.1. Toxicity

The product has not been tested.

12.2. Persistence and degradability

No data available

12.3. Bioaccumulative potential

No data available

12.4. Mobility in soil

No data available

12.5. Results of PBT and vPvB assessment

The substances in the mixture do not meet the PBT/vPvB criteria according to REACH, annex XIII.
The product has not been tested.

12.6. Endocrine disrupting properties

This product does not contain a substance that has endocrine disrupting properties with respect to non-target organisms as no components meets the criteria.

12.7. Other adverse effects

No data available

Further information

Avoid release to the environment.

SECTION 13: Disposal considerations

13.1. Waste treatment methods

Disposal recommendations

Dispose of waste according to applicable legislation. Dispose of waste according to applicable legislation.
Dispose of waste according to "Kreislaufwirtschafts- und Abfallgesetz (KrW-/AbfG)".

List of Wastes Code - residues/unused products

160506 WASTES NOT OTHERWISE SPECIFIED IN THE LIST; gases in pressure containers and discarded chemicals; laboratory chemicals, consisting of or containing hazardous substances, including mixtures of laboratory chemicals; hazardous waste

List of Wastes Code - used product

160506 WASTES NOT OTHERWISE SPECIFIED IN THE LIST; gases in pressure containers and discarded chemicals; laboratory chemicals, consisting of or containing hazardous substances, including mixtures of laboratory chemicals; hazardous waste

List of Wastes Code - contaminated packaging

150106 WASTE PACKAGING; ABSORBENTS, WIPING CLOTHS, FILTER MATERIALS AND PROTECTIVE CLOTHING NOT OTHERWISE SPECIFIED; packaging (including separately collected municipal packaging waste); mixed packaging

Contaminated packaging

Wash with plenty of water. Completely emptied packages can be recycled.

SECTION 14: Transport information

Land transport (ADR/RID)

14.1. UN number or ID number:	No dangerous good in sense of this transport regulation.
14.2. UN proper shipping name:	No dangerous good in sense of this transport regulation.
14.3. Transport hazard class(es):	No dangerous good in sense of this transport regulation.
14.4. Packing group:	No dangerous good in sense of this transport regulation.

Inland waterways transport (ADN)

14.1. UN number or ID number:	No dangerous good in sense of this transport regulation.
14.2. UN proper shipping name:	No dangerous good in sense of this transport regulation.
14.3. Transport hazard class(es):	No dangerous good in sense of this transport regulation.
14.4. Packing group:	No dangerous good in sense of this transport regulation.

Marine transport (IMDG)

14.1. UN number or ID number:	No dangerous good in sense of this transport regulation.
14.2. UN proper shipping name:	No dangerous good in sense of this transport regulation.
14.3. Transport hazard class(es):	No dangerous good in sense of this transport regulation.
14.4. Packing group:	No dangerous good in sense of this transport regulation.

Air transport (ICAO-TI/IATA-DGR)

14.1. UN number or ID number:	No dangerous good in sense of this transport regulation.
14.2. UN proper shipping name:	No dangerous good in sense of this transport regulation.
14.3. Transport hazard class(es):	No dangerous good in sense of this transport regulation.
14.4. Packing group:	No dangerous good in sense of this transport regulation.

14.5. Environmental hazards

ENVIRONMENTALLY HAZARDOUS: No

14.6. Special precautions for user

No dangerous good in sense of this transport regulation.

14.7. Maritime transport in bulk according to IMO instruments

No dangerous good in sense of this transport regulation.

SECTION 15: Regulatory information

15.1. Safety, health and environmental regulations/legislation specific for the substance or mixture

National regulatory information

Water hazard class (D): - - non-hazardous to water

15.2. Chemical safety assessment

Chemical safety assessments for substances in this mixture were not carried out.

SECTION 16: Other information

Changes

This data sheet contains changes from the previous version in section(s): 2,11.

Abbreviations and acronyms

ADR: Accord européen sur le transport des marchandises dangereuses par Route
(European Agreement concerning the International Carriage of Dangerous Goods by Road)
IMDG: International Maritime Code for Dangerous Goods
IATA: International Air Transport Association
GHS: Globally Harmonized System of Classification and Labelling of Chemicals
EINECS: European Inventory of Existing Commercial Chemical Substances
ELINCS: European List of Notified Chemical Substances
CAS: Chemical Abstracts Service
LC50: Lethal concentration, 50%
LD50: Lethal dose, 50%

Further Information

The information is based on the present level of our knowledge. It does not, however, give assurance of product properties and establishes no contract legal rights. The receiver of our product is singularly responsible for adhering to existing laws and regulations. The above information describes exclusively the safety requirements of the product and is based on our present-day knowledge. The information is intended to give you advice about the safe handling of the product named in this safety data sheet, for storage, processing,

transport and disposal. The information cannot be transferred to other products. In the case of mixing the product with other products or in the case of processing, the information on this safety data sheet is not necessarily valid for the new made-up material.
The information is based on the present level of our knowledge. It does not, however, give assurance of product properties and establishes no contract legal rights.
The receiver of our product is singularly responsible for adhering to existing laws and regulations.

(The data for the hazardous ingredients were taken respectively from the last version of the sub-contractor's safety data sheet.)